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ABSTRACT 
Nicole D. Fleming: Molecular Regulation of Cardiovascular Development and Disease 
(Under the direction of Jiandong Liu) 
 
 Congenital heart disease (CHD) represents the most common type of human birth 
defect, accounting for approximately one-third of all major congenital abnormalities. These 
structural anomalies primarily arise due to genetic and transcriptional dysregulations during 
early development and maturation of the heart. Severe CHDs can lessen a patient’s quality of 
life or lead to various life-threatening diseases like heart failure and even death. Given that 
CHDs can also give rise to adult cardiomyopathies, it is necessary to have a better 
understanding of the etiologies and the molecular regulation of factors involved in normal 
cardiac development and disease. The process from cardiogenesis to the formation of a mature 
and fully functional heart requires precise coordination of transcription factors, signaling 
molecules, and epigenetic components. In these studies, we utilized the zebrafish for its optical 
transparency, its ease of pharmacological and genetic manipulation, and its simplistic yet 
complex circulatory system to investigate the molecular basis of events that lead to defective 
hearts during early and late embryogenesis.  
A myriad of studies has shown the importance of several transcriptional and epigenetic 
factors in proper cardiogenesis, as mutations in cardiac-specific genes lead to heart defects that 
resemble those observed in human CHD patients. Furthermore, previous evidence indicates 
that as the heart matures, appropriate expansion and remodeling of the chambers are 
necessary to prevent poor contraction, increased hemodynamic burden, and compromised 
homeostasis.  
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In Chapter 2, trabeculae-deficient erbb2 zebrafish mutants were used to evaluate the 
function of trabeculae, luminal muscular protrusions within the heart, during chamber 
maturation. The data revealed that trabeculae function to possibly relieve the heart of 
mechanical-pressure overload, as absence of trabecular formation led to pathological 
hypertrophy and decreased cardiac function.  Chapter 3 explores the events of early heart 
development in zebrafish embryos that lack Ring1b, an epigenetic factor belonging to the 
Polycomb Repressive Complex 1. Data highlighted the requirement of Ring1b in SHF-mediated 
development, which has not been explored in zebrafish or mice.  
Overall, these studies provide new insights into the cellular, molecular, and functional 
regulation of distinct steps during cardiac development: SHF-mediated expansion and chamber 
maturation.
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PREFACE 
Chapter 1 provides a broad overview of cardiogenesis in vertebrate heart development. 
Particularly, it highlights the various molecular pathways, transcriptional factors and epigenetic 
mechanisms that are involved in cardiac progenitor cell processes and their ultimate 
contribution to the mature heart. Further, this section also provides information on the later 
stages of zebrafish heart development and the regulators that contribute to proper chamber 
maturation and compaction. In correlation with proper chamber maturation, I also emphasize 
various processes of physiological cardiac remodeling that impact normal and pathological heart 
development. Lastly, I highlight the value of the zebrafish as a model organism for studying 
cardiac development and disease and emphasize the therapeutic implications associated with 
the understanding gathered from the work completed in Chapters 2 and 3.  
Chapter 2 was published in Scientific Reports on June 5, 2018. Figures and text have 
been reproduced and reformatted. Over the course of development, the topology of the cardiac 
chambers matures to optimize cardiac output. During his postdoctoral work, Dr. Liu reported 
that ErbB2 signaling is essential for cardiac trabeculation in a cell autonomous manner in 
zebrafish. Though it is evident that trabeculae are important, the exact function of trabeculae in 
the heart remains unclear. In this study, we examined the mechanisms of functional 
compensation in trabeculae-deficient erbb2-/- zebrafish larvae. Our findings reveal that 
trabeculae-deficient mutants develop a hypertrophic-like phenotype in a similar fashion to adult 
mammalian hearts subjected to mechanical overload. This informed us that trabeculae helps the 
heart withstand increased chamber pressure. This work presents the first query into the cellular 
and functional consequences of loss of trabeculae and thus, the function of trabeculae during 
heart development, thereby contributing new knowledge to the field of cardiac development. 
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Additionally, these findings reveal that trabeculae-deficient erbb2-/- zebrafish can be utilized for 
in-depth, yet efficient hypertrophic studies.     
For this work, I designed and performed the majority of the experiments, analyzed the 
data and wrote the manuscript. Dr. Leigh Ann Samsa assisted in the experimental design and 
provided intellectual input. Dr. David Hassel and myself analyzed the fractional shortening data. 
Additionally, Drs. David Hassel, Li Qian, and Jiandong Liu provided intellectual input and 
supervised the work. All authors provided feedback on the manuscript. 
Chapter 3 is a potential manuscript in preparation, depending on the final contributions 
that I have made and the continuing contributions by another member in the lab. Previous work 
by van der Velden et al. (2013) revealed an essential role for the epigenetic factor, Ring1b, the 
core component of Polycomb Repressive Complex 1, in zebrafish pectoral fin and craniofacial 
development. However, the data did not highlight the cardiac defect that was also associated 
with ring1b deficiency in the zebrafish larvae hearts. Examining this heart defect was of 
particular interest to our lab because previous attempts to study Ring1b’s role in development 
had been hindered because mammalian knockout of Ring1B is embryonic lethal. In contrast, the 
zebrafish ring1b mutant can survive long enough for us to investigate the epigenetic 
mechanisms underlying early heart development, specifically cardiac progenitor cell dynamics. 
In this chapter, we aimed to characterize the phenotypes of ring1b mutants to decipher which 
process of cardiogenesis is perturbed in the mutant hearts. Our findings suggest that Ring1b 
may be involved in second heart field (SHF)-mediated development. Future results from this 
study will be invaluable for the field, as it will be one of the first in vivo studies of epigenetic 
regulation of Ring1b in early cardiac progenitors.  
Please note that figures follow the text of each chapter and references are collated at the 
end of the document.
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CHAPTER 1 GENERAL INTRODUCTION 
1.1 Cardiac Development: Regulation of Cardiac Progenitor Cells and Chamber 
Maturation 
Origin of first and second heart field progenitors 
The heart is the first organ to form during embryogenesis and its function is vital for 
survival. Previous studies in Xenopus, chick, mouse, and, most recently, zebrafish have 
provided invaluable insight into the cellular processes that take place during early cardiogenesis 
(Liu and Stainier, 2012; Olson and Srivastava, 1996; Dyer and Kirby, 2009). The developmental 
fate of cells is coordinated during gastrulation when the three germ layers, endoderm, 
mesoderm, and ectoderm, are formed and the body plan is established (Warga et al., 1990; Ho, 
1992; Dunwoodie, 2007; Yelon, 2001). The earliest events of heart development are conserved 
across vertebrates, in which naïve mesodermal cells begin to transiently express Mesoderm 
posterior 1 (Mesp1), a basic helix-loop-helix (bHLH) transcription factor, (Mespab- zebrafish 
homolog) and a subset of Mesp1-expressing cells receive precise extrinsic and intrinsic 
instructions to become specified to the cardiac fate (Devine at al., 2014; Lescroart et al., 2014; 
Cutty et al., 2012; Saga et al., 2010; Saga et al., 1999). In mice, it has been reported that there 
are two temporally distinct pools of Mesp1+ progenitor cells that eventually segregate to distinct 
anatomic regions of the heart, a process that occurs very early during gastrulation (Devine et 
al., 2014; Lescroart et al., 2014). The first heart field (FHF) progenitor pool is the first to 
differentiate into myocardial cells and extend across the midline to form the cardiac crescent 
and later the primitive heart tube. Similarly, in zebrafish, a subset of cardiac progenitor cells 
(CPCs), which are located at the lateral marginal zone at 5 hours post fertilization (hpf), 
transiently express Mespab (Fig. 2A). Then, by approximately 16 hpf, these CPCs migrate 
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within the bilateral areas of the anterior lateral plate mesoderm (ALPM) and begin to 
differentiate into mature cardiomyocytes (Fig. 1A). The differentiating cardiomyocytes, though 
not yet contractile, fuse to form the cardiac disk with developing endocardial cells. The cardiac 
disk begins to contract between 22 and 24 hpf (Fig. 1B) (Brown et al., 2016). The cardiac disk, 
then, elongates into a single heart tube from 24 to 28 hpf, primarily consisting of progenitors 
from the FHF (Figs. 1C and 2B). Following formation of the heart tube, from 28 to 36 hpf, 
relatively undifferentiated cells of the second heart field (SHF) progenitor pool begin to 
proliferate and differentiate to contribute to the poles of the linear heart tube (Figs. 1D and 2C) 
(Brown et al., 2016). This addition of SHF cells is critical for proper looping morphogenesis and 
expansion of the heart (Kelly, 2012; Camarata et al., 2010). Maintenance of SHF cells in a 
progenitor-type state longer than FHF cells possibly occurs via signals that differentially affect 
SHF cells and not FHF cells, thus, suggesting that FHF and SHF segregation is coordinated 
through different genetic regulatory networks (Rochais et al., 2009; Black, 2007; Camarata et 
al., 2010). By 48 hpf, the simple heart tube of the zebrafish gradually transforms into a two-
chambered organ (Fig. 1E) with a single compact myocardial layer overlaid by endocardial cells, 
and eventually the cardiac outflow tract, inflow tract, epicardium, and cardiac valves (Fig. 1F).  
In mouse and zebrafish, FHF and SHF progenitors can give rise to all cell types in the 
mature heart: cardiomyocytes (CMs), smooth muscle cells (SMCs), arterial and venous 
endothelial cells (ECs), fibroblasts, and cells of the conduction system (Witman and Sahara, 
2018) (Figs. 2B-C). Additionally, these progenitor-derived cells contribute to various 
components of the heart, and are delineated by the expression of specific cardiac genes. In 
mice, the left ventricle of the mature heart is primarily derived from FHF progenitors that are 
delineated by the expression of Nkx2 homeobox 5 (Nkx2.5). In contrast, the SHF contributes 
largely to the right ventricle, inflow tract and outflow tract and primarily expresses islet-1 (isl1). 
The atria are derived from a mixture of FHF and SHF cells (Fig. 3A). Importantly, zebrafish heart 
development also requires regional segregation of FHF and SHF cells and expression of 
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specific cardiac genes. Studies have revealed that FHF cells contribute to the atrium and half of 
the ventricle, while the SHF cells contribute to the other half of the ventricle, the inflow tract and 
the outflow tract (Fig. 3B) (Cavanaugh et al., 2015; de Pater et al., 2009; Zhou et al., 2011). 
Unlike the mammalian heart, the SHF in zebrafish is defined by latent TGF-β binding protein 3 
(ltbp3) expression (Zhou et al., 2011), similar to isl1 in mice, and both FHF and SHF cells 
express nkx2.5 throughout development (Figs. 2B-C). 
 
Zebrafish (Danio rerio) as a powerful model of heart development and disease 
Advantages of zebrafish as an experimental organism 
Defining CPC dynamics during cardiac development and the key regulators entail the 
use of an appropriate model system and thorough experimental approaches. Though the 
zebrafish heart is morphologically distinct from its mammalian counterpart, the heart functions 
similarly and the genes responsible for critical steps of cardiac development are conserved 
throughout vertebrates (Howe et al., 2013; Moorman and Christoffels, 2003). Current 
methodologies in most model organisms have limited resolution for understanding when and 
how single gene perturbations lead to whole organ deformities. Harnessing the power of 
zebrafish can circumvent this limitation. Due to their optical transparency, zebrafish allows for 
unprecedented access of developmental processes, with direct observation of early 
cardiogenesis, a feature not presented in many vertebrate models (Brown et al., 2016; Beis and 
Stainier, 2006; Liu and Stainier, 2012). Furthermore, the zebrafish provides an ideal model 
system in which to study cardiac development due to availability of genetic tools and the ability 
to perturb specific signaling pathways with spatiotemporal precision (Williams and Hong, 2016). 
Additionally, zebrafish can survive without a functional cardiovascular system through the first 
week of development, as they are able to meet their oxygen needs through diffusion (Stainier et 
al., 1996; Chen et al., 1996). This feature is advantageous, particularly when studying cardiac 
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defects that are embryonic lethal, because zebrafish embryos and adult zebrafish can survive 
days with cardiac abnormalities (Stainier et al., 1996; Chen et al., 1996).   
 
Zebrafish as a genetic model of heart development 
Historically, zebrafish have been used to study and understand the genetic 
implications of several heart defects. In fact, one of the initial forward, genetic screens that 
identified a plethora of novel genes and mutations affecting various developmental processes 
was performed using male zebrafish. This large-scale genetic zebrafish screen led to the 
discovery of heart of glass, silent heart, bungee, and many other genes and mutations 
(Driever et al., 1996), which were later characterized and found to play vital roles in heart 
development and homeostasis (Mably et al., 2003; Sehnert et al., 2002; Just et al., 2011). 
Hence, the zebrafish is a powerful model for discovering novel genes and investigating the 
role of various genes in cardiac development, which in turn informs what occurs in cardiac 
disease. 
 
Transcriptional regulation of CPC specification, proliferation/migration, and 
differentiation 
Coordinated transcriptional programs are essential in orchestrating the intricate cellular 
and molecular events that lead to a functioning heart. Cardiac cells are distinguished by a 
unique set of evolutionary conserved transcription factors, including Nkx2.5, T-box proteins, 
GATA proteins, HAND proteins, and ISL proteins, which are involved in various aspects of 
cardiogenesis (Table 1). 
 
Nkx2.5 
The homeobox gene Nkx2.5 is the earliest known marker of the cardiac lineage (Lints et 
al., 1993; George et al., 2015). In addition to the heart, nkx2.5 is also expressed in developing 
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pharyngeal arches (Nagelberg et al., 2015). In humans, mutations in NKX2-5 are associated 
with numerous congenital heart diseases (CHDs) (Schott et al., 1998; McElhinney et al., 2003; 
Jay et al., 2003; Elliot et al., 2003). Recent studies in mice and zebrafish provide insights into 
the functions of Nkx2.5 at early stages of cardiogenesis and throughout embryogenesis into 
adulthood (George et al., 2015). In mice, Prall et al. (2007) have demonstrated that Nkx2.5 is 
involved in coordinating transitions of FHF and SHF progenitor specification, proliferation, and 
differentiation. In vivo co-transcription assays in fibroblasts also reveal that the functionality of 
Nkx2.5 requires interactions with other cardiac restricted factors. In fact, Nkx2.5 plays a key role 
in the induction of cardiogenesis by interacting with and activating the expression of Gata4, 
Mef2C, T-box, and Hand1. Knockout of Nkx2.5 in mice is embryonic lethal (Biben and Harvey, 
1997; Tanaka et al., 1999; Lee et al., 1998; Gajewski et al., 1997). Embryos die around E9.5 
due to severe cardiac malformations; prior to looping there is arrest of the developing heart and 
noticeable down-regulation of cardiac-specific genes (Lee et al., 1998; Gajewski et al., 1997). 
Though knockdown of nkx2.5 in zebrafish embryos does not result in any obvious heart defects 
at early embryonic stages, nkx2.5 morphant defects appear during the looping stage, as the 
heart fails to loop (George et al., 2015). Nkx2.5 has been shown to be necessary for limiting 
atrial cell number and maintaining ventricular identity, as loss of nkx2.5 and nkx2.7 (another 
tinman-related gene in zebrafish) leads to elimination of all ventricular cardiomyocytes (Targoff 
et al., 2008; Targoff et al., 2013; Tu et al., 2009). Furthermore, overexpression of nkx2.5 at the 
one-cell stage in zebrafish leads to an enlarged, hyperplastic heart and dorsoventral axial 
defects (Chen and Fishman, 1996). As a master regulator of CPC dynamics, Nkx2.5 can 
potentially be used as a molecular target and modifier in CHDs.  
 
GATA 4/5/6 
The family of GATA zinc finger-containing transcription factors, particularly GATA 4/5/6, 
are involved in regulating gene expression during differentiation and morphogenesis of the 
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developing heart tissue (Laverriere et al., 1994; Morrisey et al., 1996; Kou et al., 1997). 
Together, GATA 4/5/6 share a high homologous amino acid sequence within the two adjacent 
zinc fingers that directs binding of target gene promoters. Additionally, GATA proteins have a 
conserved C-terminal zinc finger domain, which is the region found to physically interact with 
several transcription factors and co-activators in regulating cardiac gene promoters (Pikkarainen 
et al., 2004). Mutations in GATA genes also account for some of the CHDs observed in humans 
(Garg et al., 2003). In mice, Gata4 is not only expressed in the myocardium, but it is also 
expressed in the endocardium and endocardial cushions. Constitutive, partial loss of Gata4 
function was used to investigate the role of Gata4 in development. Gata4 knockout mice 
embryos died between E12.5-E.16.5 due to defects in the endocardial cushions and 
atrioventricular canal (Crispino et al., 2001; Pu et al., 2004; Rivera-Feliciano et al., 2009). 
Though NOTCH1 is the only gene that has been linked to cases of bicuspid aortic valve, 
Laforest et al. (2011) sought to determine whether endocardial-specific Gata5 plays an essential 
role in heart morphogenesis, specifically, valve development. Targeted deletion of Gata5 
(predominantly expressed in endocardial cells) in mice led to hypoplastic hearts and severe 
aortic valve defects. Furthermore, mice harboring SMC- or neural crest-restricted deletions of 
Gata6 exhibited defects in morphogenetic patterning, mainly in the outflow tract and great 
arteries (Lepore et al., 2006). In the zebrafish, gata genes are expressed in the ALPM and 
endoderm at approximately 10-24 hpf (Reiter et al., 2001; Reiter et al., 1999; Lu et al., 2016). 
The temporal requirement of these genes has been investigated using the zebrafish fau locus, 
which encodes Gata5. Reiter et al. (1999) demonstrates that gata5 (fau) mutants had almost a 
complete loss of CPCs during heart tube formation, which contributed to morphological heart 
defects such as cardia bifida.  Additional experiments in zebrafish provide further evidence that 
gata5 is required for normal expression of nkx2.5 and various aspects of myocardial 
differentiation, as expression of nkx2.5 was dramatically reduced and abnormal expression of 
myocardial sarcomere-encoding genes was observed in fau mutants. Overexpression of gata5 
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rescues the cardiac fusion defect in the mutant and leads to ectopic expression of myocardial 
genes, including vmhc, nkx2.5, and cmlc2 (Reiter et al., 1999). 
 
Tbx1/5/20 
T-box transcription factor 1 (Tbx1) encodes a transcription factor belonging to a large 
family of T-box genes that have highly conserved DNA-binding domains and are essential for 
regulating embryonic development. TBX1 has been identified as a major genetic determinant of 
the 22q11.2 deletion syndrome in humans, DiGeorge syndrome, which is highly associated with 
defects in regions of the heart that are derived from SHF progenitor cells (Yamagishi et al., 
2003). In addition to craniofacial defects, patients with 22q11.2 deletion syndrome also have 
cardiovascular defects that specifically affect the outflow tract region, such as tetralogy of Fallot 
and persistent truncus arteriosus (Yagi et al., 2003). Lineage-tracing experiments using Tbx1-
Cre transgenic mice further demonstrate that Tbx1 plays an important role in promoting 
development of the SHF-derived right ventricle and the outflow tract (Maeda et al., 2006). In 
fact, Tbx1-knockout mice recapitulate the phenotype observed in DiGeorge syndrome patients, 
while partial loss of the gene results in a milder phenotype with cardiovascular but no 
craniofacial malformations (Jerome and Papaioannou, 2001). Further, when Tbx1 is disrupted 
specifically in Nkx2.5- expressing cells, mice only had a single outflow tract with no aorto-
pulmonary septation.  
In the zebrafish, the phenotype of homozygous van gogh (vgo) tbx1 null embryos is 
strikingly similar to that observed in humans and in mice (Piotrowski et al., 2003; Nevis et al., 
2013). Recent studies have shown that tbx1, is necessary for SHF progenitor proliferation, as 
tbx1 null embryos have small ventricles, impaired cellular migration into the heart tube, and 
defective integration of SHF-derived cells to the outflow tract region (Nevis et al., 2013). Taking 
together, these findings suggest that tbx1 plays a primary role in cardiovascular and craniofacial 
development. 
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In addition to Tbx1, Tbx5 and Tbx20, have also been implicated in vertebrate cell-type 
specification, morphogenesis, and differentiation (Showell et al., 2004; Papaioannaou and 
Silver, 1998; Plageman and Yutzey, 2004). In humans, TBX5 mutations lead to Holt-Oram 
syndrome, a rare autosomal dominant disease that is characterized by upper limb abnormalities 
and heart malformations (i.e. atrial and ventricular septal defects, tetralogy of Fallot, or 
hypoplastic left heart syndrome) (Basson et al., 1997; Liu et al., 1997). In fact, patients with 
Holt-Oram syndrome have a greater than 85% incidence of CHD (Bruneau et al., 2001). 
Heterozygous null Tbx5 mice phenocopy the heart defects observed in patients with Holt-Oram 
syndrome, and homozygous null Tbx5 mice display hypoplastic atria and outflow tract and die 
by E10.5 (Bruneau et al., 2001; Newbury-Ecob et al., 1996). In zebrafish, tbx5 is expressed in 
the heart, specifically in the lateral plate mesoderm, the pectoral fins, and the eye (Begemann 
and Ingham, 2000). In zebrafish heartstrings (hst) mutants, where there is loss of tbx5 function, 
differentiation does appear to be arrested, affecting atrium and ventricle morphology. The 
zebrafish hst mutant heart fails to complete looping, displays a smaller ventricle, and eventually 
has a stretch or string-like morphology (Garrity et al., 2002). This is relative to the cardiac 
defects observed in mice or humans with Tbx5 deficiency (Basson et al., 1997; Bruneau et al., 
2001; Newbury-Ecob et al., 1996).  
 Tbx20 also has distinct roles during cardiac development. In mice, Tbx20 
overexpression leads to increased cardiomyocyte (CM) proliferation and thickening of the 
compact myocardium (Chakraborty and Yutzey, 2012). Furthermore, Tbx20 mutant mice display 
heart tubes that fail to loop and defects in CM proliferation (Cai et al., 2005; Singh et al., 2005; 
Stennard et al., 2005). The importance of Tbx20 for normal heart development is also evident 
as overexpression of tbx20 in zebrafish embryos, prior to cardiogenesis leads to CPC 
expansion, and thus an enlarged heart (Lu et al., 2017). Similar to mice, tbx20 mutant zebrafish 
embryos have unlooped hearts and defects in chamber remodeling (Lu et al., 2017).  
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Hand2 
Heart and neural crest derivatives-expressed 2 (HAND2) is a basic helix-loop-helix 
transcription factor that is expressed in the heart chambers and plays a vital role in cardiac 
morphogenesis and limp development (Vincentz et al., 2011; Srivastava et al., 1997; 
Thattaliyath et al., 2002; Morikawa and Cserjesi, 2008). In humans, HAND1 is expressed in the 
FHF and HAND2 is expressed in the SHF (Ottaviani and Buja, 2016). Recently, Lu et al. (2016) 
made a novel discovery in which a loss-of-function mutation of HAND2, p.L47P, was associated 
with increased vulnerability to tetralogy of Fallot in humans and reduction of co-activation 
between HAND2 and GATA4 or NKX2.5. In mice, Hand2 has been shown to promote the 
development of SHF-derived cardiomyocytes, as Hand2 null mice display a hypoplastic right 
ventricle and outflow tract, mostly likely due to cardiomyocyte apoptosis (Thomas et al., 1998). 
These phenotypes are further worsened with partial or conditional knockout of Hand1 (Thomas 
et al., 1998). 
In zebrafish, hand2 is expressed within the heart-forming region of the ALPM (Schindler 
et al., 2014). Hand2 has been implicated in regulating cardiomyocyte production during 
zebrafish heart development. Schoenebek et al. (2007) reported that in hand2 zebrafish 
mutants, progenitor cells residing in the ALPM region of the embryos were unable to generate 
mature cardiomyocytes. Furthermore, Schindler et al. (2014) found that overexpression of 
hand2 in zebrafish embryos led to an enlarged heart, with a noticeable increase in the size of 
the outflow tract, via the promotion of cellular division by late-differentiating SHF-derived cells. 
Together, these findings suggest that hand2 is important for specifying FHF cardiomyocytes and 
promoting proliferation of SHF cells. 
 
Isl1 and Isl2a/b 
Insulin gene enhancer protein (Isl1) is another important transcription factor in 
cardiovascular development; mutations in ISL1 in humans can also lead to CHDs (Stevens et 
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al., 2010).  Isl1 has been identified as the best-established SHF marker in mice and in vitro 
because it is expressed in the entire second heart field (Cai et al., 2003). In mice, embryos 
devoid of Isl1 display defects in development at the arterial and venous poles of the heart. 
These mice lack all structures that are derived from the SHF progenitors, including the outflow 
tract, right ventricle, and parts of the atria. Additionally, Cai et al. (2003) demonstrated the 
requirement of Isl1 for proliferation, survival, and migration of heart-forming cells, along with 
coordinating transcriptional regulation of genetic networks involved in cardiac differentiation and 
SHF development.  
Though isl1 expression is conserved in zebrafish (Hami et al., 2011), the differentiation 
defects observed in the heart are contained to only the venous pole (de Pater et al., 2009). 
Nevertheless, a recent study by Witzel et al. (2017) provides evidence that other Islet family 
members, isl2a and isl2b, are expressed in the developing zebrafish heart and have distinct 
functions during cardiogenesis. It is important to note that all members share the same 
structure, which includes two N-terminal LIM domains and one C-terminal DNA-binding domain 
(Witzel et al., 2017). The expression patterns of the proteins vary in the zebrafish, with isl2a 
being expressed in the pericardial wall and endoderm, whereas isl2b is expressed in the arterial 
pole and inner curvature of the heart. Interestingly, isl2a mutant hearts showed defective 
looping at 72 hpf, while isl2b mutants showed distinct looping defects at 48 hpf, which are 
characterized by a significantly smaller ventricle and eventually a stringy and collapsed heart 
tube (Witzel et al., 2017). In situ hybridization experiments provided additional evidence that 
is12b is required for anterior SHF development, as the expression of key regulators of 
cardiogenesis, including hand2, mef2ca/cb, and tbx20 was significantly downregulated in isl12b 




Polycomb repressive complexes play an essential role in cardiac development 
Cellular programs required for CPC specification, proliferation, and differentiation are 
tightly orchestrated by cardiac-specific transcription factors and associated chromatin regulators 
that function to activate or suppress target gene expression (Waardenberg et al., 2014). Critical 
components of the Polycomb repressive complexes (PRC1 and PRC2) have been previously 
implicated in cardiac development and disease, specifically in self-renewal, cell identity, lineage 
specification, and cell cycle control (Collinson et al., 2016; He et al., 2012; Pasini and Di Croce, 
2016; Pietersen et al., 2008; Surface et al., 2010).  
During cardiogenesis, epigenetic mechanisms influence the transcriptional activity of 
cardiac genes to enable proper CPC specification and promote differentiation. Mounting 
evidence has supported the existence of the co-operative relationship between transcription 
factors and epigenetic modifiers and has linked abnormalities in this interaction with congenital 
heart diseases (Huang et al., 2013). PRC1 and PRC2 repress gene expression primarily 
through histone modifications: histone methylation and histone ubiquitination (Fig. 4). These 
complexes have been shown to play a role in many aspects of cardiac development and 
homeostasis (Collinson et al., 2016). For example, Rae28 (also named PHC), a member of 
PRC1, is required for cardiac valve development and septation of the outflow tract through its 
role in maintaining Nkx2.5 expression. Rae28-null mice display many heart defects, including 
tetralogy of Fallot and double-outlet right ventricle (Shirai et al., 2002; Koga et al., 2002). A 
recent study in mice also reported that Ezh2, the enzymatic subunit of PRC2, stabilizes cardiac 
gene expression and prevents myocardial pathology through its role in repressing Six1, a 
transcriptional factor that functions in CPCs (Delagado-Olguin et al., 2012; San et al., 2016).  
The core components of PRC1 are Ring1A and Ring1B/Rfn2, E3 ubiquitin ligases that 
repress gene expression through mono-ubiquitination of histone H2A at lysine 119 (van der 
Stoop et al., 2008; He et al., 2012; Delagado-Olguin et al., 2012; Illingworth et al., 2015; 
Voncken et al., 2003; Morey and Helin, 2010; Kerppola, 2009). Briefly, PRC1 achieves gene 
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silencing, first, by PRC1 through Ezh2-mediated tri-methylation of H3K27 (Müller et al., 2002). 
The PcG (Polycomb group) protein in PRC1, CBX, recognizes this methylated H3K27 mark and 
recruitment of the PRC1 complex results in mono-ubiquitination of H2AK119 through the E3 
ligase activity of Ring1B (Fig. 4) (Müller and Verrijzr, 2009; Wang et al., 2004). Ring1a and 
Ring1b, the two orthologs of the Drosophilia E3 ligase dRing, are found in mammals and 
amphibians (van der Velden et al., 2012). However, only a single homologous gene to Ring1b 
had been identified in zebrafish (van der Velden et al., 2012). Interestingly, investigating the role 
of Ring1B/Rfn2 in promoting proper cardiogenesis has been hindered by developmental arrest 
at the onset of gastrulation in Ring1b knockout mice (Voncken et al., 2003; O’Carroll et al., 
2001). However, recent work has shown that in contrast to the mouse mutant, zebrafish 
embryos deficient of ring1b survive early embryogenesis but display a severe craniofacial 
phenotype (van der Velden et al., 2012). Interestingly, ring1b mutant zebrafish hearts also 
display cardiac phenotypes that have not yet been investigated. Thus, it will be important to 
study if and how Ring1b regulates key morphogenetic processes during cardiogenesis. In 
Chapter 3, I sought to address this gap in knowledge in the field by investigating what 
processes in early cardiac development is perturbed in ring1b mutants. 
 
Summary: cooperativity between cardiac transcription factors and epigenetic regulators 
As depicted in the previous section, gene expression patterns reflect a major shift in the 
transcriptional profile of the CPC population between the earlier stages of cardiogenesis (i.e. 
cardiac crescent and heart tube stages) and later phases of heart development. Nevertheless, 
there is no single gene has been shown to be responsible for cardiac specification, proliferation, 
migration, and differentiation in vertebrate development, thereby signifying some functional 
redundancy and interconnectivity in cardiac genes that direct pathways to promote 
cardiogenesis. Several cardiac transcription factors functionally interact to regulate downstream 
gene expression.  For example, without Nkx2.5, the heart does not progress beyond a primitive 
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structure, as Nkx2.5 also functions to maintain progenitor proliferation and differentiation by 
inhibiting bone morphogenetic protein (BMP) pathways (Lyons et al., 1995; Prall et al., 2007). 
Furthermore, in addition to regulating CPC dynamics, several cardiac transcription factors 
function to promote proper patterning and maturation of the early developing heart (Habets et 
al., 2002). 
There is also a high degree of cooperation between epigenetic regulators and cardiac 
transcription factors. In numerous in vitro studies investigating chromatin localization of Nkx2.5, 
Mef2a, Gata4, and Tbx5, it has been consistently reported that these factors often bind together 
at genetic loci that are co-regulated during cardiogenesis (He et al., 2011). Still, the question of 
how these transcription factors are integrated at the level of chromatin to activate transcriptional 
programs still requires further investigation. Considering the importance of cardiac transcription 
factors and the need for epigenetic control, my work in Chapter 3 aims to explore whether key 
components of the Polycomb Repressive Complex 1 (i.e. Ring1b) can also be implicated in 
creating, inhibiting, or reinforcing molecular activation of cardiac or even non-cardiac genes 
during cardiovascular development. 
 
Chamber maturation 
Emergence, propagation of “sheet-like” networks, and compaction 
Proper chamber maturation is essential for effective circulation of blood throughout the 
developing heart and organism (Samsa et al., 2015; Granados-Riveron et al., 2012). The 
zebrafish heart is morphologically more simplistic than the mammalian heart, and there are 
differences between species based on workload and circulatory demands. However, processes 
involved in patterning and regulating wall maturation are strikingly similar (Liu and Stainier, 
2012; Brown et al., 2016; Samsa et al., 2013). Moreover, a myriad of studies has provided 
evidence that genes and signaling pathways involved in key steps of cardiovascular 
morphogenesis are conversed across vertebrates (Howe et al., 2013). One of the major events 
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that occur during cardiac chamber maturation is the emergence of myocardial, “sheet-like” 
projections, termed trabeculae, in the luminal layers of the ventricle. During embryogenesis, the 
lack of trabecular formation or perturbations in cardiac trabeculae causes congenital 
cardiomyopathies. In fact, with the absence of the heart’s normal trabecular infrastructure, 
ventricular function substantially decreases, resulting in consequential effects to the organism 
(Liu and Stainier, 2012; Brown et al., 2016; Samsa et al., 2013; Liu et al., 2010).  
Initially, the embryonic zebrafish heart tube is comprised of two layers: an outer 
myocardial layer and an inner endocardial layer. Later in development, the heart tube 
undergoes expansion and extensive growth. Cardiac trabeculae begin to develop after the 
looping stage: at Carnegie stage 12 in humans, at E9.5 in mice, and at approximately 60 hpf in 
zebrafish (Liu et al., 2010; Samsa et al., 2013; Peshkovsky et al., 2011; Moorman and 
Christoffels, 2003; Sedmera et al., 2000). In zebrafish embryos, trabeculae begin to develop in 
the outer curvature of the ventricle and protrude into the ventricular lumen. More specifically, to 
form trabeculae, Liu et al. (2010) and others have demonstrated that cardiomyocytes 
delaminate from the compact myocardium and migrate through the cardiac jelly, where they 
proliferate to generate muscular trabecular ridges (Staudt et al., 2014; Samsa et al., 2013; 
Jiménez-Amilburur et al., 2016). Simultaneously, the single-cell endocardial layer expands to 
completely cover the trabecular protrusions. This process is essential, as the endocardial layer 
has been shown to be important for proper trabeculation. Zebrafish cloche mutant hearts that 
lack an endocardial layer do not form trabeculae (Stainier et al., 1995). Moreover, researchers 
have found that trabeculation does not occur in the absence of blood flow or heartbeat (Samsa 
et al., 2015; Wu, 2018; Jiménez-Amilburur et al., 2016; Granados-Riveron et al., 2012). As the 
trabecular cardiomyocytes proliferate radially and increase in length, a complex, meshwork of 
interconnected trabeculae or “sheets” of finger-like projections is formed throughout the outer 
curvature. During the final stage of trabecular growth, the trabeculae begin to thicken radially 
and become more compact (Samsa et al., 2013). Trabecular compaction also leads to 
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transformation of the spaces between trabeculae into capillaries for blood flow. Additionally, this 
remodeling process increases myocyte mass and eventually contributes to most of the working 
myocardium in the zebrafish adult heart (Samsa et al., 2013).  
Ventricular trabeculation has been suggested to facilitate nutrient and oxygen uptake 
during development, prior to coronary vascularization, and to increase cardiac output or 
hemodynamic demand in the developing embryos (Minot, 1901; Rychter and Ostádal, 1971; Liu 
et al., 2010). Nevertheless, direct evidence of how trabeculae help the heart to function 
efficiently is lacking, and my work in Chapter 2 aims to address this gap in the field by using the 
erbb2 mutant zebrafish that do not form trabeculae to assess what occurs when the heart’s 
normal trabecular infrastructure is absent. 
 
Signaling pathways essential for trabeculation 
Notch 
Notch signaling has been shown to be crucial for ventricular trabeculation and chamber 
development (Grego-Bessa et al., 2007; MacGrogan et al., 2010). In fact, mutations in Notch 
signaling components are associated with human CHDs. Canonically, mammalian NOTCH 
receptors bind to their family of ligands, including Delta or Jagged. Upon binding, the 
extracellular domain of NOTCH gets cleaved by ADAM metallopeptidase domain 17 (ADAM17), 
while the intracellular domain of NOTCH is cleaved by γ-secretase and released into the 
cytoplasm. In the nucleus, the Notch intracellular domain (NICD) forms a complex with 
transcriptional factor recombination signal-binding protein for immunoglobulin kappa J region 
(RBPJK/CBF1/Su(H)) and other factors to activate target genes (MacGrogan et al., 2010). 
NOTCH activation leads to modulation of a cascade of signaling pathways which are essential 
for trabeculation. NOTCH stimulates Ephrin B2 through its receptor Ephrin type B receptor 4 
(EPHB4) and Neuregulin1 through its receptors ErbB2/4. Additionally, NOTCH activation leads 
to activation of other pathways involved in cardiomyocyte proliferation and expansion of the 
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compact myocardial wall, namely bone morphogenetic protein 10 (BMP10) signaling. 
Interestingly, mammalian NOTCH receptors (Notch1, 2, 3, 4) and ligands (delta-like1, 3, 4 and 
jagged1, 2) show different expression patterns in the developing heart. For example, Notch1, 
Notch4, and Delta4 are expressed in the endocardial layer of the heart, while Notch2 and 
Jagged1 are expressed in the developing trabecular myocardium (Uyttendaele et al., 1996; 
Krebs et al., 2000). Endocardial-specific deletion of Notch1 and RBPJk mouse mutants show 
impaired trabeculation, decreased myocardial proliferation, and decreased expression of the 
following downstream signaling pathways: EphrinB2, Neuregulin1, and BMP10 (Grego-Bessa et 
al., 2007; Yang et al., 2012). Similarly, hypomorphic mutations of myocardial Notch2 in mice 
resulted in reduced trabeculation and a thin compact layer (Yang et al., 2012).  
Numb and Numblike are negative regulators of Notch2 activity, as they function in 
ubiquitination and degradation of Notch2 intracellular domain. In mice, Nkx2.5-Cre-mediated 
deletion of Numb/Numbl (NbNb1NK) results in increased Bmp10 and Notch2 intracellular domain 
expression. These mice also displayed trabecular and ventricular septum defects (Yang et al., 
2012). In zebrafish carrying the Notch-reporter gene expressed in cardiomyocytes, Yang et al. 
(2012) used morpholinos to knockdown zebrafish numb/numbl and assessed Notch contribution 
in the zebrafish heart. The study showed that, similarly to the increased expression of Notch2 
intracellular domain in NbNb1NK mutant mice, ectopic Notch-reporter gene activity was also 
observed in the myocardium of the zebrafish heart. In notch1b zebrafish morphants, trabecular 
formation was not observed in the outer curvature of the ventricular myocardium (Samsa et al., 
2015). Likewise, in mindbomb1 (mib1) zebrafish mutants that are defective in Notch signaling 
(Itoh et al., 2003), trabeculae were completely lacking in the ventricle at 3 days post fertilization 




Ephrin B2 is a transmembrane ligand that is essential for cardiovascular development. 
Ephrin B2 is also a direct target for endocardial NOTCH and is upstream of Neuregulin1 in the 
mammalian and zebrafish ventricle. In the vertebrate heart, Ephrin B2 and its receptor EPHB4 
are expressed in endothelial cells lining the trabecular layer of the myocardium (Wang et al., 
1998; Samsa et al., 2013). In mice deficient of Ephrin B2 or Ephrin B4, trabeculae do not form 
(Wang et al., 1998; Gerety et al., 1999). Similarly, in zebrafish larvae at 3 dpf efnb2a morphants 
lacked trabeculae in the outer curvature (Samsa et al., 2015), further signifying the importance 
of the endocardium in proper trabeculation. 
 
BMP10 
Bone morphogenetic protein 10 (BMP10) is a growth factor that belongs to the TGF-β 
superfamily and is transiently expressed in trabecular myocardium (Lowery and de Caestecker, 
2010). Bmp10 has been shown to be involved in maintaining cardiomyocyte proliferation, as 
deletion of Bmp10 in mouse embryos is embryonic lethal; Bmp10-deficient embryos die at 
E10.5 (Chen et al., 2004). Further analysis of these Bmp10-deficient embryos revealed 
hypoplastic ventricular walls and an absence of trabeculae due to a marked reduction of 
proliferation of the cardiomyocytes (Chen et al., 2004). 
Overexpression of Bmp10 in the developing ventricular myocardium in restricted Nkx2.5 
knockout mice led to prominent hypertrabeculation and cardiomyopathy (Pashmforoush et al., 
2004). These results support the notion that Bmp10 plays an important role in myocardial 
recruitment into the trabecular layer. Taken together, the Nkx2.5-Bmp10 axis is essential in the 
onset of cardiac chamber maturation, and any dysregulation of such axis is a contributor of 
trabecular defects observed in the Nkx2.5 mutant mouse (Pashmforoush et al., 2004).  
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Neuregulin/ErbB2/ErbB4 
Numerous studies in mice highlight the importance of crosstalk between myocardial and 
endocardial cells within the heart that is facilitated through Neuregulin signaling (Liu et al., 2010; 
Peshkovsky et al., 2011; Samsa et al., 2013; Olson and Srivastava, 1996; Samsa et al., 2015; 
Yelon et al., 2001). In fact, the Neuregulin signaling pathway has been deemed essential for 
cardiac trabeculation. Neuregulins are growth factors that are expressed on endothelial cells 
and signal through ErB receptor tyrosine kinases, expressed on myocardial cells, to induce 
various cellular processes such as cell proliferation and delamination (Liu et al., 2010). 
Canonically, Neuregulin1 (Nrg1) gets cleaved and binds to its receptor, ErbB4. ErbB4 
heterodimerizes with ErbB2, and ErbB2 gets phosphorylated. The kinetic activity of ErbB2 leads 
to downstream regulation of various genes involved in the formation of trabeculae (Meyer and 
Birchmeier, 1995; Lee et al., 1995). The importance of the Nrg/ErbB signaling pathway was first 
discovered by examination of ErbB2, ErbB4, and Neuregulin1 knockout mice, which either had 
reduced trabecular formation or failed to form trabeculae in the ventricle of the heart (Gassmann 
et al., 1995). These mutants eventually died at mid-gestation. Temporal and pharmacological 
inhibition of erbb2 revealed similar phenotypes in the zebrafish, which suggests that ErbB2 
signaling has both an essential and direct role in the process of trabeculation (Liu et al., 2010). 
In zebrafish, mutated nrg1 shows no gross morphological defects, and trabeculation 
appears unaffected, suggesting that another Nrg gene might be primarily responsible for 
trabecular formation in zebrafish (Samsa et al., 2016; Rasouli and Stainier, 2017). Indeed, 
Rasouli and Stainier (2017) found that, in contrast, nrg2a zebrafish mutants displayed several 
structural abnormalities, such as jaw, fin, and swim bladder defects. Importantly, nrg2a mutants 
lacked cardiac trabeculae, and the trabeculation defects appeared to mimic those seen in the 
zebrafish erbb2 mutant (Rasouli and Stainier, 2017). Noteworthy, loss of Nrg2 does not lead to 
any noticeable cardiac defects in mice. Nevertheless, these data reveal that nrg2a (which is 
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expressed in the endocardium), and not nrg1, is a key regulator in zebrafish cardiac 
trabeculation (Rasouli and Stainier, 2017). 
 
Biomechanical/hemodynamic regulators of cardiac maturation 
Cardiac morphogenesis, particularly trabeculation, is dependent on biomechanical 
forces such as those generated by cardiac contractility and blood flow (Granados-Riveron and 
Brook, 2012; Staudt et al., 2014). During embryogenesis, cardiac contraction contributes to the 
cyclic force that is imposed on the organ as blood flows through the heart. This occurs in a 
bidirectional manner. Shear stress is induced by the force parallel to blood flow over the 
endocardium, while a perpendicular force causes cyclic strain over the entire myocardial wall of 
the developing heart (Granados-Riveron and Brook, 2012; Staudt et al., 2014).  In chick and 
zebrafish, several studies have reported that inhibition or reduction of blood flow in the cardiac 
chambers completely diminishes trabecular formation. Peshkovsky et al. (2011) used zebrafish 
weak atrium (wea) mutant embryos to further decipher the influences of blood flow on 
trabeculation. Wea mutants display markedly weak blood flow, as the wea locus encodes an 
atrium-specific gene required for atrium contraction (Berdougo et al., 2003). In wea mutants, 
though some irregular thickening of the ventricular wall was initially observed, trabecular 
protrusions into the lumen did not progress toward creating myocardial ridges (Peshkovsky et 
al., 2011). These findings and others suggest that optimal blood flow through the ventricle is 
important for the progression of trabeculation. 
One way that cells detect flow or contraction is through the bending of primary cilia. Cilia 
are microtubule-based organelles that protrude from the plasma membrane and are found on 
many cell types, including endocardial cells (Samsa et al., 2013; Samsa et al., 2015). In E11.5 
Ift88-null mice, which do not form cilia, there is decreased trabeculation and ventricular dilation 
in the chambers, along with abnormal outflow tract development (Clement et al., 2009). 
Similarly, using ift88 zebrafish mutants, Samsa et al. (2015) reported that primary cilia play a 
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key role in flow detection even at low levels to upregulate notch1b and activate Notch1 in 
endocardial cells (Samsa et al., 2015). Notably, in addition to the impact of shear forces on 
endocardial cells, stretch forces “felt” by myocardial cells during normal ventricular loading can 
also induce intracellular signaling to impact trabeculation (Culver and Dickinson, 2010).  
Recent studies have shown a relationship between Notch signaling in the endocardium 
and cardiac contraction in promoting trabeculation. By using a tnnt2a morpholino to eliminate 
cardiac contraction in zebrafish larvae, Samsa et al. (2015) showed that tnnt2a morphants 
lacked trabeculae and did not express endocardial Notch (Samsa et al., 2015). Moreover, 
through loss- and gain-of-function approaches, Rasouli and Stainier (2017) showed that 
contractility and blood flow are required for endocardial expression of nrg2a. Taken together, it 
is intriguing to consider that modified hemodynamics by mechanical manipulations or mutations 
in genes encoding proteins involved in responding to shear stress, proper cardiac contraction, 
and sensing can impact the initiation or advancement of trabeculation. 
 
Cardiac remodeling during development 
Chamber pressure is another major hemodynamic cue for trabeculation and as an 
organism grows, the heart has to make structural changes over time to increase cardiac output. 
An efficient way to compensate for increased hemodynamic burden is to increase cardiac mass 
and normalize wall tension either by hyperplasia or hypertrophy of existing cardiomyocytes. 
Therefore, it is likely that cell behaviors are key contributors to the process of chamber 
emergence and maturation. 
Cardiac hypertrophy and hyperplasia are defined as cardiac remodeling processes that 
occur in response to a variety of intrinsic and extrinsic stimuli during normal development and 
stressful conditions (i.e. volume or pressure overload) (Lin et al., 2012). During normal 
development, increases in cardiomyocyte size (hypertrophy) or cardiomyocyte number 
(hyperplasia) help to facilitate chamber expansion in the heart. In mouse embryos, 
21 
cardiomyocyte enlargement progresses throughout embryonic heart development, along with 
increasing maturation of myofibrils (Hirschy et al., 2006; Lin et al., 2012). During chamber 
formation in chick embryos, cardiomyocyte proliferation contributes to two-thirds of the overall 
chamber size, while hypertrophy of individual cardiomyocytes in the outer curvature accounts 
for the remaining one-third of the chamber (Soufan et al., 2006). Furthermore, an increase in 
cardiomyocyte size has also been observed in developing hearts of zebrafish, particularly at the 
outer curvature of the emerging ventricle (Auman et al., 2007).  
 
Cardiac hypertrophy: features of concentric or eccentric hypertrophy 
Cardiac hypertrophy can be characterized in two main forms, concentric or eccentric 
(Hou and Kang, 2012). Distinct features of concentric hypertrophy include an increase in wall 
thickness with little or no reduction in chamber volume. Additionally, during concentric 
hypertrophy, the width of myocardial cells increases due to addition of sarcomeres in parallel 
within individual cardiomyocytes (Lips et al., 2003). In contrast, eccentric hypertrophy features 
minor changes to myocardial wall thickness and an increase in chamber volume (Müller and 
Dhalla, 2012; Mihl et al., 2008). On a cellular level, series addition of sarcomeres, which 
increases cardiomyocyte length, characterizes eccentric hypertrophy (Libonati, 2011).  
 
Cardiac remodeling during disease 
Cardiac hypertrophy can occur in a physiological or pathological manner, which can be 
difficult to differentiate. Along with anatomic features, physiological and pathological hypertrophy 
can also be distinguished by the functional alterations that develop. Physiological hypertrophy is 
characterized by normal or enhanced cardiac contractility, while pathological hypertrophy is 
associated with decreased cardiac function (Hou and Kang, 2012). Initially, the heart 
compensates for stress by increasing cardiac mass; however, if the stimuli remain untreated, 
cardiac hypertrophy can lead to heart failure or death. The hallmarks of pathological 
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hypertrophy include enlargement of individual cardiomyocytes, disarray of myofibrils 
(sarcomeres that stack in parallel), re-activation of fetal transcriptional programs, fibrosis in the 
extracellular matrix, and decreased cardiac function (Carreño et al., 2006; Samak et al., 2016). 
To investigate the pathogenesis of cardiac remodeling via hypertrophy and/or 
hyperplasia in zebrafish, Sun et al. (2009) used tr265/tr265 zebrafish that display anemic stress 
due to a Band 3 mutation that disrupts erythrocyte formation. Data showed that many features 
of cardiomyopathy observed in mammals, including muscular disarray and re-activation of fetal 
genes (ex. ANF), and severe arrhythmia, were recapitulated in the adult zebrafish mutant. In 
addition to myocyte hypertrophy, Sun et al. (2009) showed that myocyte hyperplasia is involved 
in every stage of the remodeling process, with contribution from proliferating cardiomyocytes 
and differentiating cardiac progenitor cells. Interestingly, since the tr265/tr265 zebrafish survived 
the longest when only hyperplasia was prominent in the heart, it is suggested that myocyte 
hyperplasia might be a better remodeling strategy than cardiac hypertrophy (Sun et al., 2009). 
My work in Chapter 2 aims to undercover the specific cellular and molecular remodeling 
behaviors of cardiomyocytes that are in a trabeculae-deficient zebrafish ventricle.  
As previously mentioned, in pathological cardiac remodeling, many fetal genes and other 
molecular factors are re-employed. Factors that are re-activated include atrial natriuretic factor 
(ANF), cardiac transcription factors (Mef2c, Nkx proteins, and Gata proteins), co-regulators, 
microRNAs, and/or those involved in epigenetic regulation (Dirkx et al., 2013). Though each of 
these factors act independently on a different level of genetic regulation, they also form a highly 
interconnected network with each other to promote transcriptional activation of various genes 
(Dirkx et al., 2013). Therefore, these genetic networks offer numerous therapeutic targets to 
reduce the aberrant expression of fetal genes, for example, and effectively address the adverse 
remodeling processes of the failing heart.  
Natriuretic precursor peptide type A, Nppa, (also known as ANF) and Nppb are major 
markers for the hypertrophic response in cell culture and for the development of hypertrophy 
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and other heart failure-related diseases in animal models. In human hearts of approximately 6 
and 12 weeks of development, NPPA was expressed in the atrial chamber myocardium and the 
ventricular trabeculae (Christoffels et al., 2004). Furthermore, variants in the human NPPA gene 
are associated with hypertension, stroke, coronary artery disease, heart failure, and obesity 
(Song et al., 2015). To investigate the pattern and level of Nppa and Nppb expression living 
mice, Sergeeva et al. (2014) used Nppa/Nppb double reporter transgenic mice, in which the 
bioluminescent signal from Luciferase correlated with Nppa expression, and the intensity of red 
fluorescence was associated with expression of Katushka and Nppb.  Sergeeva at al. (2014) 
performed transverse aortic constriction (TAC) as an experimental model for pressure-overload 
cardiac hypertrophy. Data showed that Nppa expression significantly increased in the TAC 
mouse ventricle compared to the control ventricle. In addition to being a functional marker of 
stress, Nppa is also a structural marker. In situ hybridization in mice showed that Nppa was 
restricted to the trabecular layer in the heart. Furthermore, in a Nppa-GFP knock-in mouse line, 
Tian et al. (2017) showed that endogenous Nppa expression was largely restricted to trabecular 
cardiomyocytes at E11.5 and E12.5, particularly in the left ventricle. Likewise, in zebrafish, nppa 
is also expressed in the heart and in the trabecular layer (Grassini et al., 2018; Aumen et al., 
2007). 
 
mTOR signaling in cardiac hypertrophy and the effects of rapamycin treatment 
Several intracellular signaling pathways have been implicated in mechanical overload-
induced cardiac hypertrophy. Common pro-hypertrophy effectors that are activated include 
mitogen-activated protein kinases (with ERK1/2), AKT, calcineurin, and phosphatidylinositol 3-
kinase (PI3K). All pathways play a pivotal role in myocyte growth and survival in physiological 
hypertrophy (van Berlo et al., 2013). One of the most studied and well-characterized pathways 
that has been shown to be involved in pathological cardiac hypertrophy is the mammalian target 
of rapamycin (mTOR) pathway. Physiologically, it is also required for embryonic cardiovascular 
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development and for maintaining cardiac homeostasis in postnatal life (Laplante and Sabatini, 
2009; Sciarretta et al., 2018).  
mTOR is a serine/threonine kinase, belonging to the phosphoinositide kinase-related 
kinase family. The mTOR pathway involves two functional complexes: mTOR complex 1 
(mTORC1) and mTOR complex 2 (mTORC2). mTORC1 is more characterized (Laplante and 
Sabatini, 2009; Guertin and Sabatini, 2007). The core components of mTORC1 are regulatory-
associated protein of mTOR (RAPTOR) and mammalian lethal with SEC13 protein 8 (mLST8), 
which are involved in substrate recruitment along with subcellular localization and kinase 
activity, respectively. mTORC1 is the main regulator of cellular growth by promoting various 
anabolic processes such as autophagy, protein synthesis, and lipid synthesis within the tissue 
(Laplante and Sabatini, 2009). Concerning protein synthesis, mTORC1 activates S6 kinase-1 
(S6K1) by direct phosphorylation at Thr389, leading to initiation of translation through multiple 
mechanisms (Peterson et al., 2009; Sciarretta et al., 2018). 
mTOR was reported as a direct target of rapamycin. Rapamycin is a lipophilic macrolide 
that effects cellular growth by forming a gain-of-function inhibitory complex with FK506-binding 
protein of 12 kDa (FKBP12), thereby leading to mTORC1 inhibition (Guertin and Sadatini, 
2007). Several genetic and pharmacological approaches in mouse models have been used to 
investigate mTOR modulation during cardiovascular development, physiology, and stress. In 
humans, treatment of patients after cardiac transplantation with rapamycin significantly 
attenuated left ventricular hypertrophy (Kushwaha et al., 2008). mTOR inhibition using 
rapamycin in a TAC mouse model, resulted in decreased cardiac hypertrophy and cardiac 
dysfunction (Shioi et al., 2003; McMullen et al., 2004). Furthermore, in another study using 
rapamycin in a mouse model of LEOPARD syndrome, a genetic disorder, Marin et al. (2011) 
reported a decrease in cardiac hypertrophy and myocardial disarray. Following a forward 
genetic screen in zebrafish, Ding et al. (2011) identified the ztor zebrafish mutant. 
Haploinsufficency of the ztor heterozygous zebrafish, induced by doxorubicin (DOX), displayed 
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a 65% reduction in TOR expression, allowing the zebrafish to survive to adulthood. Myocyte 
enlargement was diminished with short-tern rapamycin treatment using DOX induction. When 
investigating long-term effects of mTOR inhibition, ztor fish displayed cardioprotective features 
characterized by improved cardiac function, reduced mortality, lessened apoptosis and 
autophagy, and little pathological remodeling (i.e. parallel sarcomere addition) (Ding et al., 
2011). Taken together, mTOR is a key therapeutic target for addressing many hypertrophic-
associated cardiovascular diseases. More specifically, based on work presented in Chapter 2, 
rapamycin may be a promising therapy for patients with trabeculae-associated diseases. 
 
Relevance to current research 
Although several mice models of cardiac hypertrophy have been developed, it usually 
takes months for these mice to develop hypertrophic phenotypes. The advantage of studying 
the hypertrophic phenotype in the trabeculae-deficient erbb2 zebrafish mutant is that it only 
takes four days for these animals to show hypertrophic phenotypes (Lin et al., 2012; Fleming et 
al., 2018), thereby facilitating the study of the molecular and cellular mechanisms involved in 
compensatory growth of the myocardium. Likewise, PcG proteins, such as Ring1B, are also 
conserved in zebrafish as well as their accompanying epigenetic marks (San et al., 2016). 
Since the ring1b mutant zebrafish survives early embryogenesis, unlike Ring1b mutant mice, 
the zebrafish allows for detailed analysis of early cardiac phenotypes.  
 
Early and late manifestations of CHDs  
As previously noted, genetic mutations in genes that are essential during early 
cardiogenesis can lead to various CHDs. For example, DiGeorge syndrome (DGS) is one of the 
most common diseases, affecting approximately 1 in 4000 live births (Yagi et al., 2008). It is 
caused by the deletion of a small segment of chromosome 22 at a location designated q11.2. 
This deletion results in the abnormal development of numerous body systems (McDonald-
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McGinn and Sullivan, 2011). Importantly, though genetics (i.e. genetic mutations) influence 
many of the structural anomalies, the subsequent morphogenetic defects that develop are what 
primarily lead to CHD symptoms, morbidity, and mortality. Individuals with DiGeorge syndrome 
have craniofacial defects, aortic arch malformations, and conotruncal heart defects. Several 
knockout experiments in mice and zebrafish have identified Tbx1 as a major factor in the onset 
of the malformations in DGS, particularly relating to the heart (Yamagishi et al., 2003; Yagi et 
al., 2008). Mutations in the same gene can also cause multiple phenotypes in the heart. For 
example, mutations in Nkx2.5 can lead to atrial or ventricular septal defects, tetralogy of Fallot 
and conduction defects. Similarly, patients with mutations in GATA4 can display pulmonary 
stenosis and double outlet right ventricle (Ottaviani and Buja, 2016). 
In patients, CHDs also develop due to inappropriate execution of late cardiac 
morphogenic processes. Presumably, CHDs that perturb early cardiac morphogenesis would 
produce severe phenotypes such that they would be embryonic lethal and thus not observable 
in the patient population. One of the many forms of CHDs is called left ventricular non-
compaction (LVNC), which is characterized by prominent trabeculae and large recesses 
between trabeculae (Morcos et al., 2015; Samsa et al., 2013). Ventricular non-compaction in 
patients with LVNC has been defined as a morphogenetic abnormality that arises from defects 
in trabeculation and compaction. Furthermore, various genetic mutations have been identified to 
be associated with this structural defect, particularly those found in sarcomere-encoding genes 
and calcium-handling genes (Samsa et al., 2013). Noteworthy, human patients with LVNC 
cardiomyopathy can survive to adulthood, but often suffer from heart failure, arrhythmias and/or 
sudden cardiac death (Ottaviiani and Buga, 2016; Jenni et al., 1999). In addition to structural 
defects, patients with LEOPARD syndrome or other CHDs also develop hypertrophic 
cardiomyopathy, a condition that further reduces the function of the diseased heart (Marin et al., 
2011). Therefore, there is a critical need to understand the molecular basis of heart 
27 
development and CHD-associated hypertrophic cardiomyopathy to facilitate the design of novel, 
more precise therapies for CHDs and to alleviate the associated hypertrophic defects. 
 
Potential therapeutic interventions for CHDs through experimental approaches 
The heart defects that infants are afflicted with range from mild to severe and nearly 
50% of affected infants require clinical intervention (i.e. surgery) within the first year of life (Chin 
et al., 2012). Additionally, adults with CHDs, such as LVNC, are often treated for the 
hypertrophic cardiomyopathy that usually develops, with the primary goal of improving cardiac 
function. Still, the need for more effective therapies in the clinical setting remains. Animal 
models have contributed immensely to current knowledge and ongoing advancements in the 
cardiovascular field. However, a more comprehensive understanding of cardiac developmental 
processes will help researchers to develop more extensive approaches that aim to investigate 
multiple aspects of cardiomyocyte dynamics in the developing heart. In turn, this will provide a 
foundation for establishing efficient therapeutic strategies in CHDs, acquired myopathies, and 
disease modeling. Numerous studies have highlighted that CPCs have the potential to be 
utilized for stem cell therapies, particularly for personalized medicine, since CPCs have the 
capacity to give rise to all cell types of the mature heart (Amini et al., 2017; Cyganek et al., 
2013). In fact, clinical trials have already been carried out via implantation of cardiac resident 
progenitor cells, bone marrow-derived stem cells, or induced pluripotent stem cells (iPSCs) as a 
source of new functional cardiomyocytes (Yang et al., 2015; Tsilimigras et al., 2017).  
Patients with CHDs, such as LVNC, have a high incidence of hypertrophic or dilated 
cardiomyopathy, arrhythmia, complete atrioventicular blockage, and embolization, which can 
lead to cardiac death or transplantation (Morcos et al., 2015). Though the prevalence of patients 
with trabeculae-associated hypertrophic CHDs is rather low, it still remains relevant that most 
CHDs can lead to pathological hypertrophy, which is one of the main outcomes of LVNC.  
Therefore, therapeutic interventions that include the use of small molecules can be employed to 
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target pathways or regulators involved in hypertrophy in the hopes of attenuating or reversing 
the adverse effects of the disease. Essentially, generating “diseases in a dish” or better yet, 
utilizing appropriate model organisms and techniques have proven and will continue to be vital 
for efficiently modeling a broader range of cardiovascular diseases observed in patients to 








Figure 1 Simplified schematic of zebrafish heart development 
(A-E) Dorsal views of heart development in zebrafish larvae from 16 to 48 hours post fertilization. (F) 
Cross-sectional view of zebrafish larvae heart at 3 to 7 days post fertilization with trabecular, epicardial, 






Figure 2 Cardiac progenitor cell dynamics and transcriptional regulation: specification, 
proliferation/migration, and differentiation 
(A) A subset of mesodermal cells is specified to the cardiac fate. (B) First heart field cells are the first to 
differentiate into all cell types of the heart and form the primitive linear heart tube. (C) In a second wave of 
differentiation, second heart field progenitors add to the poles of the heart tube and ultimately, give rise to 





Figure 3 FHF and SHF-derived cells contribute to different compartments of the 
vertebrate heart 
(A) Schematic of adult mammalian heart with FHF-derived cells in LV and parts of LA and RA. SHF-
derived cells give rise to RV, Aorta, PA, and parts of LA and RA. (B) Simplified zebrafish 2-chambered 
heart at 5 days post fertilization with FHF-derived cells contributing to half of ventricle and atrium, while 
SHF-derived cells are located in other half of ventricle, OFT, and IFT. FHF, first heart field; SHF, second 





Figure 4 Schematic of canonical Polycomb pathway  
(1)  PRC2 component, EZH2, methylates H3K27. (2) Following H3K27 tri-methylation, PRC1 is 
recruited following recognition of the repressive H3K27 mark by CBX, allowing the PRC1 component 
RING1B to ubiquitinate lysine 119 of histone H2A, stabilizing the repressive mark. (3) This results in 
chromatin compaction and inhibition of RNA polymerase II elongation, thus leading to gene silencing.  
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Table 1 Chapter 1 Summary of genes involved in human, mouse, and zebrafish 
cardiogenesis and disease  
 CHDs and/or functional defects 
Gene name Gene Human Mouse Zebrafish 
Nk2 Homeobox  
5 
NKX2.5 Atrial septal defects, AV 
conduction defect, 















GATA4/5/6 Septal defects, CM 





due to pressure 
overload-induced 
hypertrophy 






TBX1 DiGeorge syndrome, 
outflow tract 
abnormalities, Holt-Oram 
syndrome, upper limb 
abnormalities, septal 
defects 
Right ventricle and 
outflow tract 
defects, hypoplastic 
atria and OFT, 
septal defects 
Outflow tract 
defect, SHF cell 
proliferation 
defect, unlooped 
heart, defect in 
chamber 
remodeling 
Heart and neural 
crest derivatives-
expressed 2 
HAND2 Tetralogy of Fallot  Hypoplastic right 
ventricle and 








ISL1 Patent ductus arteriosus 
and ventricular septal 
defects 




tract, and parts of 
atria) 









CHAPTER 2 RAPAMYCIN ATTENTUATES PATHOLOGICAL HYPERTROPHY CAUSED BY 
AN ABSENCE OF TRABECULAR FORMATION 
2.1 Historical Context 
Cardiovascular diseases remain the leading cause of death in the United States and 
worldwide (Thomas et al., 2018). More specifically, congenital heart diseases are the leading 
cause of birth defects among infants (Bruneau et al., 2008). Defects observed in babies and 
adults are sometimes due to improper cardiac maturation (Samsa et al., 2013; Chin et al., 
2012). During embryonic development, trabeculae, which are highly organized, muscular 
structures, are formed through apical constriction and delamination of cardiomyocytes within the 
compact myocardial wall. As development continues, trabeculae undergo compaction, thus 
promoting increased surface area within the developing heart (Sedmera et al., 2000; Liu et al., 
2010; Peshkovsky et al., 2011; Staudt and Stainier, 2012; Samsa et al., 2013; Moorman and 
Christoffels, 2003). Perturbations in trabeculation may result in various forms of CHDs, such as 
left ventricular non-compaction (LVNC), which is characterized by the presence of excessive 
trabecular recesses in the muscle wall of the heart. Furthermore, complete failure to form 
trabeculae is embryonic lethal across species (Jenni et al., 1999; Samsa et al., 2013). 
ErbB2 signaling pathway is one of the few genetic pathways identified so far to be 
directly implicated in the molecular regulation of cardiac trabeculation (Liu et al., 2010). In the 
absence of myocardial ErbB2 or its endocardial-derived ligand Neuregulin (Nrg1), cardiac 
trabeculation is completely blocked (Liu et al., 2010; Gassmann et al., 1995). Detailed 
transplantation and lineage studies in zebrafish have revealed that erbb2 signaling promotes 
cardiac trabeculation by directly regulating cardiomyocyte migration (Liu et al., 2010).  
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Although several mouse models of cardiac hypertrophy have been developed, it usually 
takes months for these mice to develop hypertrophic phenotypes (Hasenfuss et al., 1998; 
Camacho et al., 2016). The advantage of studying the hypertrophic phenotype in erbb2 mutants 
is that it only takes four days for these animals to develop hypertrophic phenotypes (Fleming et 
al., 2018), thereby facilitating the study of the molecular and cellular mechanisms involved in 
compensatory growth of the myocardium. Furthermore, zebrafish embryos with severe cardiac 
defects can still survive and continue to develop in a relatively normal fashion for several days 
(Stainier, 1996; Brown et al., 2016). Data presented in Chapter 2.2, below, provides 
physiological context for the function of trabeculae by elucidating how the heart compensates 

















2.2 Rapamycin Attenuates Pathological Hypertrophy in the Absence of Trabecular 
Formation 
Introduction 
The function of the heart is intimately linked to its structure. In order to meet an 
increasing physiological demand of the growing embryo, the developing vertebrate heart 
undergoes extensive chamber topological remodeling to increase total cardiac output. Most 
notably is the formation of cardiac trabeculae, the mesh-like luminal projections within 
ventricular myocardium (Sedmera et al., 2000; Liu et al., 2010; Peshkovsky et al., 2011; Staudt 
and Stainier, 2012; Samsa et al., 2013; Moorman and Christoffels, 2003). Cardiac trabeculation 
is a complex and tightly regulated morphogenetic process that involves cardiomyocyte (CM) 
apical constriction followed by CM depolarization and remodeling of myocardial cell-cell 
adhesion (Staudt et al., 2014; Jiménez-Amilburur et al., 2016). These highly coordinated cellular 
events ultimately lead to CM delamination and emergence of trabeculae (Liu et al., 2010). 
Despite substantial progress in our understanding of the cellular and molecular basis of cardiac 
trabeculation, the exact function of trabeculae in the heart remains unclear. Cardiac 
trabeculation is essential for life, as subtle perturbations in trabeculation are associated with 
many congenital heart diseases (CHDs), and complete failure to form trabeculae leads to 
embryonic lethality across different species (Liu et al., 2010; Jenni et al., 1999; Zhang et al., 
2013; Gassmann et al., 1995). Yet, how loss of trabeculae leads to a lethal phenotype remains 
an open question. 
Although the fundamental cellular and morphological changes associated with cardiac 
trabeculation occur mostly in the myocardium, this process requires crosstalk at the molecular 
level between endocardial and myocardial cells (Liu et al., 2010; Peshkovsky et al., 2011; 
Samsa et al., 2013; Olson and Srivastava,1996; Samsa et al., 2015; Yelon et al., 2001). 
Nrg/ErbB signaling constitutes one of the most important signaling pathways required for 
cardiac trabeculation, and is a key node for this crosstalk. Neuregulins, expressed on 
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endocardial cells, are part of the epidermal growth factor receptor ligand family and signal to the 
myocardial cells through its ErbB4-ErbB2 receptor complex and are essential for trabeculation 
in multiple model systems (Samsa et al. 2013; Samsa et al., 2015; Meyer and Birchmeier, 1995; 
Lee et al., 1995).  Mouse embryos deficient of Nrg1, ErbB2 or ErbB4 all fail to form trabeculae 
(Gassmann et al., 1995). Likewise, loss of Nrg/ErbB2 signaling in zebrafish embryos results in a 
complete absence of trabecular formation (Liu et al., 2010). By taking advantage of the unique 
attributes of zebrafish embryos, Liu et al. (2010) demonstrated that pharmacological inhibition of 
ErbB2 signaling right before cardiac trabeculation completely blocked this process from 
occurring, suggesting an immediate and direct effect of Nrg/ErbB2 signaling on trabecular 
formation. As such, the zebrafish erbb2 mutant is advantageous to investigate the cellular and 
functional consequences when the heart loses its normal internal cardiac trabecular structure.  
In this study, we found that erbb2 mutant ventricles exhibit an increase in ventricular 
cardiomyocyte cross-sectional area and myofibril size. This cardiac phenotype is reminiscent of 
hypertrophic growth of an adult mammalian heart subjected to mechanical overload. 
Consistently, we found that the expression of hypertrophic marker gene, nppa, was elevated in 
erbb2 mutants compared to controls. Intriguingly, inhibition of Target of Rapamycin (TOR) 
signaling by rapamycin suppressed erbb2 mutant hypertrophic-like (HL) growth phenotype and 
rescued cardiac function. Additionally, cell transplantation experiments indicate the erbb2 
mutant HL phenotypes are due to a loss of cardiac trabeculae. Together, our findings suggest 
that trabeculae serve to enhance contractility for efficient cardiac function and that defects in 
this process lead to wall-stress induced pathological hypertrophic remodeling. 
 
Results  
erbb2 mutant hearts exhibit hypertrophic-like phenotypes  
While the embryonic heart requires cardiac contraction to initiate trabecular formation 
(Samsa et al., 2015; Rasouli and Stainier, 2017), failure of cardiac trabeculation could cause the 
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developing heart to suffer not only structural defects, but also mechanical disturbance that might 
lead to further myocardial damages. We have previously reported that larvae homozygous for 
the erbb2st61 allele encoding a premature stop codon, from here on referred to as erbb2-/- or 
erbb2 mutants, develop progressive systolic and diastolic dysfunction (Liu et al., 2010). The 
reduction in fractional shortening in erbb2 mutant hearts observed in Liu et al. (2010) is a 
probable consequence of the loss of trabeculation, suggesting that cardiac trabeculae are 
important for proper cardiac function and overall workload efficacy of the ventricle. To evaluate 
the underlying cardiomyocyte defects associated with the cardiac dysfunction observed in erbb2 
mutant hearts, we bred the erbb2st61 allele onto Tg(myl7:mKateCAAX) and Tg(myl7:Cypher-
EGFP) transgenic backgrounds to label the CM plasma membrane and Z-band of cardiac 
sarcomere, respectively (Fig. 5A). 
Using these genetically encoded fluorescent protein labels, we assessed cardiomyocyte 
structure in erbb2-/- larvae by confocal microscopy compared to control larvae carrying at least 
one copy of the wildtype erbb2 allele. This technique allowed us to measure the outer compact 
myocardial wall thickness, distance between sarcomeres, and Z-line length at the trabeculation 
stages (Fig. 5A). When comparing outer compact myocardial wall, we observed a significant, 
albeit rather mild, increase in the myocardial wall thickness in erbb2 mutant ventricles compared 
to control ventricles at 3 days post fertilization (dpf), when trabeculae are small in the ventricle 
(Figs. 10A-1B'). At 5 and 7 dpf, when the control heart becomes extensively trabeculated, the 
difference in the outer compact myocardial wall thickness between the two genotypes was even 
greater. For instance, at 5 and 7 dpf, the outer compact myocardial wall thickness increased by 
75% and 88% in erbb2 mutant ventricles relative to control ventricles, respectively (Figs. 5B-5C' 
and 5F; Figs. 10E-F'). In contrast, it only increased by 23% at 3 dpf (Fig. 5F). Since the 
zebrafish ventricular compact myocardial wall is one-cell thick (D’Amico et al., 2007), the 
compact myocardial wall thickness is equivalent to compact CM cross-sectional area. We also 
measured Z-band size as an indicator of ventricular sarcomere thickness. Cardiac remodeling in 
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response to mechanical overload also includes the addition of sarcomeres in parallel to existing 
sarcomeres (Carreño et al., 2006). Consistent with the compact wall thickness phenotype, Z-
band length increased in the erbb2 mutant hearts by 5 dpf. Though comparable at 3 dpf, with 
control hearts, ventricular sarcomere thickness of erbb2 mutant hearts became significantly 
increased on 5 dpf and 7 dpf by 26.2% and 27.6%, respectively (Figs. 5D-E"' and 5G; Figs. 
10C-D'' and 10G-H"). Suggesting that sarcomeric function is normal, and that the sarcomeres 
are structurally intact, the distance between Z-bands was unchanged in erbb2 mutants (Fig. 
5H). Taken together, these data suggest that erbb2 mutant ventricles that lack trabeculae 
exhibited an increase in ventricular CM cross sectional area and myofibril size, a phenotype 
indicative of the cellular changes that underlie biomechanical overload-induced cardiac 
hypertrophy (Heineke and Molkentin, 2006). 
Next, we addressed whether the HL phenotypes exhibited by erbb2 mutant were 
pathological. At the molecular level, pathological cardiac hypertrophy is typically associated with 
upregulation of marker genes, such as natriuretic peptide precursor A (nppa) (Deschepper et 
al., 2001; Deschepper et al., 2002; Kushwaha et al., 2008). nppa is conserved in zebrafish and 
its embryonic expression has been well characterized (Becker et al., 2012). During cardiac 
development, as cardiac trabeculae start to form, nppa expression is down-regulated in the 
ventricular compact myocardium, and becomes restricted in cardiac trabeculae (Sergeeva et al., 
2014). To evaluate whether nppa was upregulated in erbb2 mutants, we first selected putative 
erbb2 mutants based on a supernumerary neuromast phenotype detectable by 3 dpf with vital 
dye MitoTracker. Nppa expression was observed mainly in the trabecular layer of erbb2 control 
hearts (Figs. 10I-I’). Though erbb2 mutant ventricles are completely devoid of cardiac 
trabeculae, whole mount in situ hybridization revealed strong nppa expression in the ventricular 
compact myocardium (Figs. 10J-J’). More importantly, RT-PCR analysis of isolated control and 
mutant hearts demonstrated that the expression of nppa was dramatically upregulated in erbb2 
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mutant compared to control (Fig. 5I), suggesting a pathological nature of erbb2 mutant 
hypertrophic phenotypes. 
 
Inhibition of TOR signaling attenuates erbb2 mutant hypertrophic-like phenotype 
To identify signaling pathways essential for erbb2 mutants to develop HL phenotypes, 
we performed a targeted small molecule screen to inhibit signaling pathways known to be 
involved in regulating cardiac hypertrophy (Carreño et al., 2006; Marin et al., 2011; Sciarretta et 
al., 2014; Ding et al., 2011; Hardt et al., 2011). We treated control and erbb2 mutant larvae 
carrying plasma membrane and sarcomere reporters with 1% DMSO or small molecules at 2.5 
dpf, just prior to emergence of the first trabeculae, then assessed ventricular compact wall 
thickness and cardiac sarcomere structure at 5 and 7 dpf (Fig. 6A). Inhibition of TOR signaling 
with rapamycin at a concentration of 1 µM suppressed the increased compact myocardial wall 
thickness and Z-band length phenotypes in erbb2 mutant at both 5 dpf (Figs. 6B-I' and 6R-S) 
and 7 dpf (Figs. 6J-Q' and 6R-S). Narrowing in on the TOR pathway, we observed similar 
changes to compact myocardial wall thickness and myofibril length when TOR was inhibited via 
0.5 µM Rapamycin (Figs. 11A-C) or 0.5 µM Torin 1 (Figs. 11D-F), another potent inhibitor of the 
TOR pathway. Notably, rapamycin treatment did not cause any compact myocardium and 
sarcomere defects in control hearts, nor did it have any effect on distance between Z-line in the 
mutant hearts (Fig. 6T). Together, our data strongly indicates inhibition of TOR signaling by 
rapamycin treatment suppressed erbb2 mutant HL phenotypes. Thus, erbb2 mutant hearts 
develop hypertrophy in a TOR-dependent manner. 
 
Rapamycin treatment improves impaired heart function in erbb2 mutant 
The above experiments indicate that inhibition of TOR signaling by rapamycin 
suppressed HL phenotypes in erbb2-/- larvae hearts. We next wanted to test if this attenuation of 
HL phenotypes translated into an enhancement or even further deterioration of cardiac function 
41 
(Fig. 7A). Consistent with previous studies (Liu et al., 2010), we found that erbb2 mutants 
exhibited progressive cardiac dysfunction. At 3 dpf, the ventricular fractional shortening (FS) of 
erbb2 mutants is comparable to that of control animals, but the mutant displayed significantly 
reduced FS at 5 dpf, which declined even further at 7 dpf (Fig. 7B). Consequently, erbb2 mutant 
animals started to die at 7 dpf (Fig. 7C). However, no significant difference on heart rate was 
observed between control and erbb2 mutants (Fig. 7D). Interestingly, upon treatment with 
rapamycin from 2.5 dpf onwards, the erbb2 mutant hearts displayed significantly improved 
ventricular FS at 5 dpf compared to DMSO-treated erbb2 mutant hearts (p = 0.0499). Though, 
this improvement in heart function is not sustainable over time (Fig. 7E). Furthermore, we did 
not notice any significant difference in heart rate between DMSO and rapamycin-treated groups 
(Fig. 7F). Together, these findings suggest that the TOR pathway is an important regulator of 
the HL phenotype and inhibition of TOR signaling delayed disease progression of the erbb2 
mutant hearts.  
 
erbb2 mutant HL phenotype results from the absence of trabecular formation 
As the erbb2 mutant HL phenotypes are reminiscent of hypertrophic growth of an adult 
heart subjected to mechanical overload (Heineke and Molkentin, 2006), we hypothesize that 
these HL phenotypes could be due to mechanical disturbance as a result of the absence of 
trabecular formation. Yet, it is also possible that the HL phenotypes could result from a loss of 
erbb2 function cell-autonomously in the cardiomyocytes. To distinguish these possibilities, we 
generated genetic mosaic embryos whereby erbb2 mutant or control cells were transplanted 
into wildtype embryos. The host embryos were allowed to develop until 5 dpf before monitoring 
CM cross-sectional area and myofibril size of the transplanted cells. In these experiments, we 
transplanted blastomeres from erbb2-/- or control donors that carried Tg(myl7:mKateCAAX), 
Tg(myl7:Cypher-EGFP) transgenes into Tg(myl7:rasGFP); Tg(myl7:Cypher-EGFP) hosts. 
Transplanted donor cardiomyocytes were labeled in red by Tg(myl7:mKateCAAX), and thus, 
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were readily distinguishable from the host derived cells (Fig. 8A). Noteworthy, the transplanted 
mKateCAAX-positive control cells populated both the compact and trabecular layers (Figs. 8B-
B'''). The mKateCAAX-positive erbb2 mutant cells failed to contribute to the trabeculae and were 
found exclusively in the compact layer (Figs. 8E-E"'). Most importantly, we found that the cross-
sectional area of the transplanted erbb2 mutant cardiomyocytes was not significantly different 
from that of the transplanted control cardiomyocytes (Figs. 8B-B''', 8E-E''', and 8H) and their 
neighboring compact cardiomyocytes (Figs. 8I-J). Similarly, there was no significant difference 
in Z-line length (Figs. 8C-D, 8F-G, and 8K) or the distance between Z-lines (Fig. 8L) between 
transplanted control and erbb2 mutant cardiomyocytes. Thus, these data suggest that ErbB2 
does not directly regulate compact ventricular myocardial wall thickness, and that erbb2 mutant 
HL phenotype is caused by the absence of trabecular formation. 
 
Discussion 
In this study, we sought to investigate the molecular mechanisms that impact the 
remodeling process when the heart loses its normal internal cardiac trabecular structure. We 
present in vivo evidence that cardiac trabeculae have an important physiological function during 
embryonic heart development. Interestingly, we found erbb2 mutant ventricles exhibit an 
increase in ventricular CM cross-sectional area and myofibril size, likely due to an absence of 
trabecular formation (Fig. 9), suggesting that trabeculae-deficient ventricles undergo 
hypertrophy to stabilize the workload/cardiac output imbalance in the heart. 
It has been speculated that cardiac trabeculae serve to increase cardiac output, facilitate 
the exchange of oxygen and nutrient prior to formation of the coronary vasculature (Sedmera et 
al., 2000; Liu et al., 2010; Samsa et al., 2013; Moorman and Christoffels, 2003). Nevertheless, 
there have been very few studies that examine exactly how trabeculae help the heart function in 
an efficient manner. Mice lacking Nrg1, ErbB4, or ErbB2 fail to form trabeculae and thus die at 
approximately E10.5 (Gassmann et al., 1995). The early embryonic lethality of these systems 
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disallows for detailed characterization of the trabeculae-deficient hearts at a cellular level. 
Zebrafish embryos do not require a functional circulatory system during the first week of life and 
thus can survive very severe cardiac defects (Stainier, 2001; Beis and Stainier, 2006). Thus, we 
took advantage of the zebrafish erbb2 mutant that lacks trabeculae to decipher the 
consequence of an absence of trabecular formation and found that trabeculae-deficient hearts 
exhibited HL phenotypes reminiscent of those of an adult mammalian heart subjected to 
mechanical overload. As an organism grows, the heart undergoes morphological changes to 
meet the demand of increase workload. Our finding thus suggests that trabeculae serve to 
enhance contractility and that defects in this process lead to wall-stress induced pathological 
hypertrophic remodeling.  
Pathological cardiac hypertrophy is induced by mechanical pressure-overload (Heineke 
and Molkentin, 2006). The intracellular signaling activated by the mechanical stress imposed on 
the myocardium induces extensive structural and physiological changes to offset the 
mechanical stress. Currently, there are no viable methods to directly measure the 
intraventricular radial wall stress “felt” by cardiomyocytes. To circumvent this gap of knowledge, 
future studies are needed to focus on using 3D computational models of the function in the 
zebrafish heart to extract quantitative assessments of radial wall stress. Specifically, numerical 
simulations can be used to compare radial wall stresses generated during contraction of the 
control and erbb2 mutant hearts to readily obtain spatial and temporal distributions of radial wall 
stresses. 
Recent studies have identified multiple cell signaling pathways to be involved in cardiac 
hypertrophy, including TOR (Carreño et al., 2006; Marin et al., 2011; Sciarretta et al., 2014; 
Ding et al., 2011; Hardt et al., 2011). Signaling through the TOR pathway has been shown to be 
an important regulator of normal cardiac growth and pathological hypertrophy (Heineke and 
Molkentin, 2006; Marin et al., 2011). We examined signaling pathways that could attenuate the 
hypertrophic response in erbb2 mutant hearts. Our small-molecule pharmacological studies 
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indicated that inhibition of TOR signaling suppressed erbb2 mutant HL growth phenotype (Fig. 
9). The TOR pathway has been implicated as a potential therapeutic target for 
cardiomyopathies because inhibition by rapamycin, a specific inhibitor of TORC1, has been 
shown to be cardio-protective (McMullen et al., 2004; Shioi et al., 2003). In human patients, 
rapamycin treatment following heart transplantation significantly reduced left ventricular 
hypertrophy (Kuwahara et al., 2003). Intriguingly, in mice, pharmacological administration of 
rapamycin prevents cardiac hypertrophy induced by transverse aortic constriction and reverses 
hypertrophic cardiomyopathy in a model of CHD LEOPARD syndrome (Marin et al., 2011). 
These findings suggest a common pathological signaling pathway of CHD-associated 
hypertrophic cardiomyopathy across zebrafish, mouse and humans.   
In this present study, we also provide evidence suggesting that erbb2 mutant hearts 
undergo pathological hypertrophy probably due to mechanical overload because they lack 
trabeculae rather than to deficiency in ErbB2 signaling. Our study cannot completely rule out the 
possibility that HL phenotypes are manifested as a consequence of ErbB2 deficiency and are 
independent of the absent of trabecular formation. In fact, previous studies have shown that 
various trabeculation-deficient zebrafish embryos that have impaired flow and cardiac 
contractions display distinct differences in CM behavior and formation of protrusions 
(Peshkovsky et al., 2011; Staudt et al., 2014; Chi et al., 2008). Because of the transparency of 
the zebrafish embryos and the ease of genetic manipulation, the unique HL phenotype caused 
by the absence of trabeculae in ErbB2-deficient larvae will provide us a great opportunity to use 
zebrafish as a model to assess molecular events and mechano-transduction signaling pathways 
involved in CHD-associated hypertrophic cardiomyopathy. In addition, the small size and 
permeability of zebrafish embryos also enable high-throughput small molecule screens to 
identify novel suppressors of disease phenotypes. The zebrafish erbb2 mutant thus could serve 
as an in vivo platform for phenotype-based drug screen to identify novel small molecules 
capable of suppressing CHD-associated hypertrophic cardiomyopathy. 
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Materials and Methods 
Zebrafish husbandry and strains 
All animals were maintained at the aquaculture facility of the University of North Carolina 
at Chapel Hill in accordance with Institutional Animal Care and Use Committee approved 
protocols37. We used the following transgenic and mutant lines: erbb2st61 (Lyons et al., 2012) 
mutants, Tg(myl7:mKateCAAX)sd11 (Lin et al., 2012), Tg(myl7:Cypher-EGFP)xu061 (Yang and Xu, 
2012), Tg(myl7:ras-GFP)s883 (D’Amico et al., 2007). 
 
Confocal imaging and analysis 
Zebrafish embryos were anesthetized using 1X Tricaine (Sigma) and mounted with 1% 
low-melting agarose (Sigma) in embryo medium or system water for optimal visualization of 
heart. Heartbeat was ceased before imaging using 5-10X Tricaine (Sigma). Images were 
obtained with an Olympus Fluoview 1000MPE, multiphoton, upright confocal microscope 
equipped with a 20X XLPlan (NA 1.0) water immersion objective with 3.0X, 2.5X, or 10X digital 
zoom and 1024x1024 pixels resolution. Confocal z-stacks were collected using the Fluoview 
software with a 2.50 µm or 1.05 µm step size acquisition through the heart tissue. 488 nm and 
599 nm lasers were used to excite GFP and RFP. Each channel was acquired sequentially to 
avoid bleed through and signal attenuation due to increasing depth was taken into account by 
using the software's brightness correction algorithm. Confocal images were collected for a 
minimum of 5 embryos for each condition. Data was analyzed using ImageJ (Schneider et al., 
2012) software.   
 
Compact myocardial wall and sarcomere measurements 
ImageJ (Schneider et al., 2012) software was used to analyze confocal z-stacks of heart 
tissue. For ventricular compact myocardial length, a line (total of 12 lines) was drawn from one 
end of the plasma membrane to the next of individual cardiomyocytes through different mid-
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chamber z-stacks to obtain an average measurement from a minimum of 5 embryos. An 
average measurement of distance between sarcomeres was obtained by drawing a line (N = 
20) from the middle of one Z-line to the middle of the neighboring Z-line for a minimum of 5 
embryos. To obtain sarcomere Z-line length, Z-lines of individual cardiomyocytes were outlined 
and average length of Z-lines and area of cardiomyocytes were recorded for a minimum of 5 
cardiomyocytes.   
 
Cardiac function measurements  
Embryos were genotyped using MitoTracker Red (Life Technologies) and immobilized 
with 0.5X Tricaine (Sigma). Embryos were mounted using 1% low-melting agarose (Sigma) and 
oriented for optimal observation of hearts at 3, 5, and 7 dpf. After agarose solidified, embryos 
were incubated with fresh egg water for 20 minutes to remove any residual Tricaine and renew 
normal cardiac contraction. A Leica M205C fluorescence stereomicroscope and software were 
used to visual and record live imaging of Tg(myl7:mKateCAAX); Tg(myl7:Cypher-EGFP) 
positive hearts at 120X or 200X magnification. For each condition, heartbeats per minute were 
obtained from 15-second movies. Additional details are as previously described (Lin et al., 
2012). Assessment of functional shortening was performed as previously described (Liu et al, 
2010). Briefly, for each embryo, the average diameter at end systole (fully contracted ventricle) 
and end diastole (fully dilated ventricle), during three cardiac cycles, was obtained using 
VirtualDub software (available at http://www.virtualdub.org) and ImageJ (Schneider et al., 2012). 
  
Survival curve 
Zebrafish embryos from interbreeding erbb2+/- Tg(myl7:mKateCAAX); Tg(myl7:Cypher-
EGFP) fish were screened at 3 dpf using MitoTracker Red to identify erbb2 control and mutant 
embryos. Survival was recorded daily from N = 3 tanks of 50 embryos each per genotype. 
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Chemical inhibition of hypertrophic pathways  
Pharmacological inhibitors were stored in DMSO (Fisher Scientific) stocks. Embryos 
were treated with drugs, 0.5 µM or 1 µM rapamycin (Santa Cruz Biotech) or 0.5 µM Torin 1 
(Cayman Chemical), diluted in egg water (1.5 mL stock salts added to 1 L distilled water) and 
supplemented with 0.003% 1-phenyl 2-thiourea (PTU) (Sigma) and DMSO to 1% final. Control 
embryos were incubated with 1% DMSO vehicle. Embryos were dechorionated and treated with 
DMSO, rapamycin or Torin 1 at 2.5 dpf until 5 dpf and 7dpf.  
 
Whole heart isolations and quantitative RT-PCR 
At 3, 5, and 7 dpf zebrafish embryos were euthanized and hearts were isolated with 
forceps using a Leica M205C fluorescence stereomicroscope and placed in lysis buffer prior to 
RNA isolation. At least 10 hearts were pooled per sample and RNA was extracted using a 
RNeasy Plus Mini kit (Qiagen). cDNA synthesis was performed immediately following RNA 
isolation protocol using iScript cDNA synthesis kit (Invitrogen). Quantitative RT-PCR was 
performed using cDNA, Sybr Green reagent (Roche) and gene-specific primers in triplicates 
using an Applied Biosystem Viia7 RT-PCR machine (Life Technologies). The primer sequences 
used in this study are provided in Table 2. The delta-delta CT method was used to normalize 
desired genes to the endogenous housekeeping gene vmhc and determine the relative fold 
change gene expression.   
 
Whole-mount in situ hybridization  
In situ hybridization was performed as previously described (Thisse and Thisse, 2008; 
Liu et al., 2010). Briefly, genotyped zebrafish embryos were fixed with 4% paraformaldehyde in 
1X PBS at 5 dpf and placed in 4 °C cold room overnight. Embryos were then washed in 1X PBS 
(3x 10 minutes), incubated for 30 minutes in 100% methanol then stored in 100% methanol at –
20 °C. Zebrafish embryos were rehydrated in PBST and incubated in proteinase K (20 mg/ml 
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diluted in PBT 2:2000) for 45 minutes then post-fixed in 4% PFA. The tail of erbb2 mutant 
embryos were removed using a fine forceps, and both control and mutant embryos were placed 
in the same tube to ensure consistent handling throughout the staining process. Hybridization 
with probe of interest was done overnight in 65-70 °C water bath. Following washes, embryos 
were incubated with anti-DIG-AP antibody (Roche) overnight at 4 °C. Subsequent color 
development was achieved following addition of NBT/BCIP. Embryos were then stored in stop 
solution at 4 °C overnight. Next, embryos were transfer to 100% glycerol and placed at 4 °C 
overnight. Embryos were mounted in 100% glycerol for imaging. Whole-mount embryos were 
visualized using a Leica MZ16F fluorescence stereomicroscope with Retiga 2000R camera and 
images were collected using the QCapture software. 
 
Cell transplantation 
Mosaic embryos were obtained using erbb2 control or mutant Tg(myl7:mKateCAAX); 
Tg(myl7:Cypher-EGFP) and Tg(myl7:ras-GFP);Tg(myl7:Cypher-EGFP) double transgenic lines. 
Cells were removed from donor embryos and transplanted into the marginal zone of stage-
matched host embryos. Embryos were visualized using a Leica S6D microscope. Cells were 
transplanted using borosilicate thin wall capillary glass tubing needles (Warner Instruments) and 
a CellTram vario (Eppendorf) apparatus that allowed for precise control of pressure 
transmission with oil. Host embryos with mKateCAAX-expressing cells were allowed to develop 
until 5 dpf. Donor embryos from in-crossing erbb2st61 heterozygotes were kept to determine 
genotype of donor cells as previously described (Lyons et al., 2012). Embryos were mounted for 





The data shown in the graphs are represented as mean ± SEM. Statistical significance 
was determined between groups with a two-tailed Student’s t-test.   
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Figure 5 erbb2 mutant develops HL phenotypes 
(A) Schematic of method utilized for obtaining myocardial wall and myofibril measurements. (B,C) Mid-
chamber confocal sections of control and erbb2-/- hearts, respectively. (B',C') Magnified high-resolution 
images of compact myocardial wall and trabecular regions marked by dotted box in B, C. Yellow arrows 
point to length of CM along compact myocardial wall. White arrows point to trabeculae. (D,E) Maximal 
projection of confocal Z-stacks of ventricle. (D'-D''', E’-E'') Magnified high-resolution images of compact 
myocardium outlined in white in D and E revealing sarcomere structures of two CMs in control and erbb2-
/- ventricles, respectively. (F-H) Quantification of compact myocardial wall thickness (n = 6-10), Z-line 
length (n = 9-10), and distance between Z-lines (n = 8-10), at 3, 5, and 7 dpf from control and erbb2-/- 
hearts. (I) Expression of nppa in whole hearts isolated from erbb2 control or erbb2-/- larvae (n = 10-15). 
Data are represented as mean ± SEM. *p ≤ 0.05, ** p = 0.0025, *** p = 0.0004 and ****p < 0.0001 by 




Figure 6 Inhibition of TOR signaling attenuates erbb2 mutant HL phenotypes  
(A) Schematic of experimental design. (B,D,F,H,J,L,N,P) Mid-chamber confocal sections of control and 
erbb2-/- hearts treated with DMSO or rapamycin at 5 and 7 dpf. (B',D',F',H',J',L',N',P') Magnified high-
resolution images of compact myocardial wall and trabecular regions marked by dotted box in 
B,D,F,H,J,L,N,P. Yellow arrows point to length of CM along compact myocardial wall. White arrows point 
to trabeculae. (C-C',E-E',G-G',I-I') Magnified high-resolution images of compact myocardium revealing 
sarcomere structures of CMs at 5 dpf. (K-K',M-M',O-O',Q-Q') Magnified high-resolution images of 
compact myocardium revealing sarcomere structures of CMs at 7dpf. (R-T) Quantification of compact 
myocardial wall thickness (n = 7-15), Z-line length (n = 5-10), and distance between Z-lines (n = 5-12) at 5 
and 7 dpf from DMSO or rapamycin-treated control and erbb2-/- hearts. Data are represented as mean ± 




Figure 7 Rapamycin treatment improves impaired heart function in erbb2 mutant 
(A) Schematic of experimental design. (B) Quantification of ventricular fractional shortening of control and 
erbb2-/- larvae at 3, 5, and 7 dpf (n = 10). (C) Quantification of percent survival over ~2 weeks of control 
and erbb2-/- clutchmates from N = 3 tanks of 50 embryos each. (D) Quantification of heart rate in beats 
per minute of control and erbb2-/- larvae at 3, 5, and 7 dpf (n = 9-10). (E) Quantification of ventricular 
fractional shortening of DMSO or rapamycin-treated control and erbb2-/- larvae at 3, 5, and 7 dpf (n = 9-
16). (F) Quantification of heart rate in beats per minute of DMSO or rapamycin-treated control and erbb2-/- 
larvae at 3, 5, and 7 dpf (n = 4-11). Data are represented as mean ± SEM. *p = 0.0499,  ***p ≤ 0.001, and 
****p < 0.0001 by Student's t test. Note: Asterisk in E indicates a significant difference compared to 5 dpf 




Figure 8 erbb2 mutant HL phenotypes result from the absence of trabecular formation 
(A) Schematic of transplantation experiment resulting in transplanted blastomeres from 
Tg(myl7:mKateCAAX);Tg(myl7:Cypher-EGFP) erbb2 control or erbb2-/- donors into Tg(myl7:rasGFP); 
Tg(myl7:Cypher-EGFP) wild-type hosts. (B-B'',E-E") Mid-chamber confocal sections of control and erbb2-
/- donor CMs, respectively, in wild-type host ventricle. (B'",E'") Magnified high-resolution images of 
compact myocardial wall and trabecular regions marked by dotted box in B", E". Yellow arrows point to 
length of donor CM (yellow line) along compact myocardial wall. White arrow heads point to length of host 
CM (white line) along compact myocardial wall. White arrows point to trabeculae. (C,F) Maximal 
projection of confocal Z-stacks of ventricle. (D,G) Magnified high-resolution images of compact 
myocardium, revealing sarcomere structures of control and erbb2-/- donor CMs, respectively, in wild-type 
host ventricle at 5 dpf. (H-J) Quantification of cross-sectional area of erbb2 control donor and erbb2-/- 
donor CMs (H), erbb2 control donor and host CMs (I), and erbb2-/- donor and host CMs at 5 dpf (J). (K) 
Quantification of Z-line length of erbb2 control donor and erbb2-/- donor CMs at 5 dpf. (L) Quantification of 
distance between Z-lines of erbb2 control donor and erbb2-/- donor CMs at 5 dpf. Data are represented as 




Figure 9 Schematic diagram illustrating that trabeculae-deficient erbb2 mutants undergo 




Figure 10 erbb2 mutant exhibits more pronounced HL phenotype over time 
(A,B,E,F) Mid-chamber confocal sections of erbb2 control and erbb2-/- hearts at 3 and 7 dpf. (A',B',E',F') 
Magnified high-resolution images of compact myocardial wall and trabecular regions marked by dotted 
box in A,B,E,F. Yellow arrows point to length of CM (white line) along compact myocardial wall. White 
arrows point to trabeculae. (C-C'',D-D'',G-G",H-H") Magnified high-resolution images of compact 
myocardium, revealing sarcomere structures of two CMs. (I, J) Representative images of whole-mount in 
situ hybridization of nppa in erbb2 control and erbb2-/- hearts, respectively. (I’, J’) Magnified images of 




Figure 11 Inhibition of TOR signaling with lower concentration of Rapamycin and Torin1 
attenuates erbb2 mutant HL phenotypes 
(A-C) Quantification of compact myocardial wall thickness (n = 3-8), Z-line length (n = 4-9), and distance 
between Z-lines (n = 4-8) at 5 and 7 dpf from DMSO or (0.5 µM) rapamycin-treated erbb2 control or 
erbb2-/- hearts. (D-F) Quantification of compact myocardial wall thickness (n = 3-8), Z-line length (n = 5-8), 
and distance between Z-lines (n = 3-8) at 5 and 7 dpf from DMSO or (0.5 µM) Torin 1-treated erbb2 
control or erbb2-/- hearts. Data are represented as mean ± SEM. ****p < 0.0001 by Student's t test.  
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Table 2 Chapter 2 qRT-PCR primer sequences 
Gene Forward (5'-3') Reverse (3'-5') 
Vmhc GAGACGAACAACCTTCTGC AGCAAGCTTACGGCCTCTTT 
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2.3 Significance and Future Directions 
Significance   
 Studies in zebrafish have suggested that trabeculae function to increase cardiac output 
and allow for the uptake of nutrients and oxygen prior to formation of the coronary vasculature 
(Sedmera et al., 2000; Liu et al., 2010; Samsa et al., 2013; Moorman and Christoffels, 2003). 
However, direct evidence of how trabeculae help the heart to function efficiently is lacking. In 
order to address this gap in knowledge, we explored the function of trabeculae by investigating 
what occurs when the heart loses its normal, internal structure. The study described in Chapter 
2.2 is a comprehensive analysis of the physiological importance of trabeculae during heart 
development. Defects in myocardial remodeling (i.e. trabeculation) in infants and adults can 
lead to left ventricular dilation or hypertrophy and noncompaction cardiomyopathy (Towbin et 
al., 2015; Marcos et al., 2014; Wu et al., 2018). Our findings revealed that in the absence of the 
heart’s trabecular infrastructure, cardiomyocytes undergo pathological hypertrophy. Our inquiry 
into the mechanisms underlying the hypertrophic phenotype observed in the trabeculae-
deficient erbb2 mutant reveals that the mTOR pathway is essential, as inhibition of the TOR 
pathway with a small molecule, rapamycin, suppresses the pathological phenotype. In addition 
to contributing to understanding how trabeculae functions, this finding has implications for better 
therapies for individuals with trabeculae-associated and hypertrophic cardiovascular diseases. 
 
Future Directions 
Determine how cardiomyocytes sense and respond to mechanical forces in a trabeculae-
deficient environment 
An important aspect of the trabeculae-associated hypertrophic response observed in 
the erbb2 mutant that needs further investigation is whether the HL phenotypes are due to 
increased radial wall stress. Mechanical force is essential in cardiac trabeculation, as mutations 
in genes encoding proteins that are involved in cardiac contraction, sensing, and responding to 
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blood flow in the developing heart result in altered trabeculae morphogenesis that can cause 
septal malformations and substantial defects to the ventricular wall architecture (Granados-
Riveron et al., 2012; Samsa et al., 2013; Lin et al., 2012). These changes are evident in 
zebrafish embryos with occluded inflow and outflow tracts and in zebrafish cfk, tnnt2, and amhc 
mutants (Bartman et al., 2004; Berdougo et al., 2003). Mice deficient in Myl7, Tnnt2, or Ncx1 
genes display defective cardiac chamber infrastructure with thin ventricular walls and 
underdeveloped trabeculae (Huang et al., 2003; Nishi et al., 2008; Cho et al., 2000). Similarly, in 
humans, ACTC1 and MYH6 mutations lead to perturbed cardiac contraction and result in a 
multitude of septal defects (Mattson et al., 2008; Ching et al., 2005; Monserrat et al., 2007; 
Grandos-Riveron et al., 2010; Grandos-Riveron et al., 2012; Budde et al., 2017). Taken 
together, these findings suggest that dysregulation in trabeculae-deficient mutants could be due 
to increased radial wall stress. However, there are no feasible methods to directly measure the 
intraventricular radial wall stress “felt” by cardiomyocytes. Therefore, a quantitative modeling 
approach can be used to further evaluate the hypothesis that the erbb2 mutant hypertrophic 
phenotype is a remodeling process to help the heart handle increased mechanical forces in the 
absence of cardiac trabecular formation. 
Previous studies using 2D modeling of the zebrafish heart in cross section demonstrate 
that trabecular regions are exposed to unique flow patterns (Battista et al., 2018). In 
collaboration with computational biologists, 3D computational models of the functional zebrafish 
heart can be constructed using confocal z-stacks of the zebrafish heart to extract accurate 3D 
geometry during contraction of 5 and 7 dpf control and erbb2 mutant hearts. Spatial and 
temporal distributions of radial wall stresses can be readily extracted from the simulations.  
Performing these simulations in the zebrafish heart can be technically challenging. It is 
vital to select appropriate modeling assumptions without sacrificing complexity and structural 
detail to validate biological relevance and obtain accurate yet predictive results. One method 
that can be implemented to validate the 3D models is comparing the resulting motion of the 
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heart and the movement of the blood to measurements that will be derive from videos of the 
beating hearts. Hedrick et al. (2008) describe a technique in which the contraction motion can 
be quantified over time by tracking the cardiac wall. The spatial and temporal flow fields can be 
compared to flow rates estimated by tracking blood cells in transgenic zebrafish embryos.  
To further evaluate the role of mechanical forces in trabeculae-deficient erbb2 mutant-
induced hypertrophic remodeling and investigate whether reducing mechanical forces is enough 
to reverse the hypertrophic phenotype, treatment with blebbistatin can be performed. 
Blebbistatin is a highly potent myosin-II specific ATPase inhibitor of cardiac contraction (Farman 
et al., 2008; Limouze et al., 2004). To this end, using Tg(myl7:mkateCAAX); Tg(myl7:Cypher-
EGFP) to label the myocardium and sarcomere structures, respectively, control and mutant 
embryos can be incubated with vehicle (DMSO) or blebbistatin starting at 3 dpf. At 5 and 7 dpf, 
confocal images should be collected for at least 20 DMSO- or blebbistatin-treated control or 
erbb2 mutant embryos to compare ventricular compact wall thickness and myofibril size 
between DMSO- and blebbistatin-treated erbb2 mutant embryos. Since blebbistatin acts to 
block cardiac contraction by inhibiting myosin-II specific ATPase activity, it might be challenging 
to distinguish whether rescue of erbb2 mutant phenotypes by blebbistatin treatment is due to 
inhibition of myosin-II activity or inhibition of cardiac contractility. Inhibiting cardiac contraction 
with nisoldipine (Kass et al., 1982), which acts by a completely different mechanism, can 
circumvent this issue.   
 
Identify novel pathways and genes involved in the trabeculae-deficient hypertrophic 
process 
Developing animal models that can inform or better predict human cardiovascular 
diseases can prove challenging if key factors in disease biology are unknown. The small size 
and permeability of zebrafish embryos can be used in high-throughput chemical screens to 
identify novel small molecule suppressors of erbb2 HL phenotypes (Lin and Stainier, 2012; 
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Williams et al., 2016; Beis and Stainier, 2006). Though it has been reported by my work 
(mentioned in Chapter 2.2) and other studies that manipulating known pathways of hypertrophy 
(i.e. mTOR) has an effect on erbb2 HL phenotypes, it is possible that the erbb2 mutant HL 
response might also involve novel mechanisms. Future studies aiming to address this area of 
research can incorporate fluorescent activated cell sorting (FACS) combined with RNAseq or 
gene expression microarrays for transcription enrichment profiling. The lab has an established 
protocol for single-cell sequencing using zebrafish embryos that can be modified for isolating 
pure control and erbb2 mutant cardiomyocytes at various time points (i.e. 3, 5, and 7 dpf) for 
single-cell sequencing. Whole mount in situ hybridization should be used to validate predicative 
expression profiles of candidate genes. Pathway analysis and subsequent pharmacological 
inhibition of selected pathways or complexes can be applied to further define important 
regulators in CHD-associated hypertrophic cardiomyopathies.  
 
Characterize difference between delaminating trabecular cardiomyocytes versus 
compact wall cardiomyocytes 
Though the functional importance of trabecular formation during cardiac maturation has 
been studied, the question of how particular compact wall cardiomyocytes are “selected” or 
“predetermined” to delaminate and become trabecular cardiomyocytes remains unclear. 
Understanding the cellular mechanism behind normal maturation of the heart chambers, 
particularly trabeculation, will provide substantial knowledge to the field that may lead to new 
paradigms for therapeutic discovery and development. Insights into the dynamic behavior of 
future trabecular cardiomyocytes reveal that while cardiomyocytes enter the trabecular layer 
from the compact layer via abluminal constriction (apical constriction) (Jimenez-Amilburur et al., 
2016; Staudt et al., 2008) and by extending their protrusions, neighboring cardiomyocytes 
maintain the compact layer by occupying the empty space left behind (Jimenez-Amilburur et al., 
2016). As delamination occurs, it is essential that tight contact between adjacent 
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cardiomyocytes is maintained as cells from the compact layer are “pushed out”. Intriguingly, 
Cherian et al. (2016) reported that cdh2 (N-cadherin) molecules, mediated by ErbB2 signaling, 
localize to the basal side of cardiomyocytes in the compact layer to promote direct interactions 
between delaminating cardiomyocytes, thus preventing complete detachment from the compact 
layer.  
Neuregulin/ErbB2/ErbB4 signaling is notably one of the most important pathways 
required for trabecular formation and the expression of genes like Neuregulin is regulated by 
Notch signaling in endocardial cells, in mouse and zebrafish. Interestingly, Jimenez-Amiliburu et 
al. (2016), using numerous Notch signaling zebrafish reporter lines, identified a subpopulation of 
compact layer cardiomyocytes expressing the Notch reporter gene adjacent to cells undergoing 
apical constriction. According to the authors, expression of Notch signaling in non-delaminating 
cells was key in preventing extrusion into the trabecular layer (Jimenez-Amilburur et al., 2016).  
Still, how cardiomyocytes in the trabecular and compact layer are specified is unclear. 
To address this gap in knowledge, transgenic zebrafish embryos expressing specific trabecular 
or compact layer markers can be used to explore cellular mechanisms that regulate 
cardiomyocyte delamination. Nppa is specifically expressed in trabecular cardiomyocytes, while 
Hey2 has been shown to be active in the compact myocardial layer in mouse and zebrafish 
(Tian et al., 2017; Wu, 2018; Sanchez-Iranzo et al., 2018). To this end, cells from 
Tg(nppa:ZsYellow); Tg(hey2: DsRed) erbb2 control and mutant zebrafish embryos can be 
isolated at various time points during trabeculation (i.e. prior to, during, and after delamination) 
for FACS and single-cell analysis. To avoid any possibilities of contamination between layers, 
scRNAseq can be used on all the GFP+ cardiomyocytes from Tg(myl7:GFP) embryos, which 
can be computationally sorted into subpopulations and later verified. Cellular analysis of these 
two population of cells may reveal differentially expressed genes and unique signaling pathways 
between the two zones.
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CHAPTER 3 CHARACTERIZING THE ROLE OF RING1B IN SECOND HEART FIELD 
DEVELOPMENT 
3.1 Historical Context 
Congenital heart disease (CHD) is the leading cause of perinatal mortality, accounting 
for approximately 1% of live births and an unknown percentage of embryos that die in utero 
(Bruneau et al., 2008). CHD often features structural and functional abnormalities that arise 
from defective development of the heart during embryogenesis, particularly those affecting 
cardiac structures derived from second heart field (SHF) progenitors (Amini et al., 2017; Chin et 
al., 2012). Recent work in mammals has shown that multipotent, late differentiating cardiac 
progenitor cells (CPCs) of the SHF migrate into the heart tube and contribute to the formation of 
the right ventricle, outflow and inflow tract, and parts of the atria. In zebrafish, SHF-derived cells 
give rise to the inflow tract, outflow tract, and half of the ventricle of the 2-chambered heart. 
(Brand et al., 2003; Buckingham et al., 2005; de Pater et al., 2009; Dunwoodie et al., 2007). 
Subtle perturbations in this SHF contribution to the developing heart are the most common 
cause of congenital heart diseases, and severe deficiencies in SHF function leads to embryonic 
lethality (Granados-Riveron et al., 2012). Scientific research geared towards deciphering the 
cellular and molecular mechanisms that orchestrate SHF development is thus crucial to improve 
therapeutic approaches for cardiovascular diseases. Furthermore, understanding CPC 
specification, proliferation, and differentiation into the major cell types of the vertebrate heart 
can facilitate the generation of novel therapeutic strategies for cardiac repair and regeneration in 
patients suffering from acquired cardiomyopathies. Chapter 3 aims to shed light on the role 
epigenetic repressors, specifically Ring1b of the Polycomb Repressive Complex 1, play in 
zebrafish cardiogenesis. 
64 
3.2 Characterizing the Role of Ring1b in Second Heart Field Development 
Introduction 
Heart development requires precise regulation of cardiac progenitor cell (CPC) 
specification, proliferation, and differentiation in a highly organized spatial and temporal manner 
(Devine et al., 2014; Heisenberg et al., 2008; Warga et al., 1990; Bondue et al., 2011; Tam et 
al., 1997). Progenitor cells contribute to the formation of the functional heart by making single-
cell-level decisions towards the cardiac lineage and are derived from two progenitor pools. 
During vertebrate heart development, progenitors from the first heart field (FHF) give rise to the 
initial heart tube, and second heart field (SHF) progenitors differentiate after the linear heart 
tube is formed and contribute to most of the mature heart: the outflow tract, right ventricle, and 
majority of the atria in mammals and the outflow tract, inflow tract, and ~50% of the ventricle in 
zebrafish (Buckingham et al., 2005; Wu et al., 2008; Evans et al., 2010; Srivastava et al., 2006; 
Kelly, 2012). Though some aspects of CPC patterning have been studied (Devine et al., 2014; 
Lescroart et al., 2014; Scott, 2012; Brand, 2003), epigenetic regulation of CPC specification and 
differentiation, and ultimate contribution of CPCs to the mature heart still demands further 
investigation.  
 Since earlier defects in FHF dynamics can result in embryonic lethality, mutations in 
genes involved in regulating cardiogenesis are likely to impact the late-differentiating SHF 
population (McCulley and Black, 2012; Brand, 2003; Bruneau, 2008). Indeed, many common 
congenital heart defects in humans are caused by perturbations in SHF-derived tissues, 
including septal defects and transposition of the great arteries (Kelly, 2012). Furthermore, 
intermediate defects in SHF function compromise elongation and rotation of the outflow tract 
(OFT), ultimately leading to rightward shifting of the aorta relative to the ventricles. This is a 
defining feature of the complex congenital heart defects, tetralogy of Fallot and double outlet 
right ventricle (Need et al., 2013). Any gene implicated in SHF biology becomes a candidate for 
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causing congenital heart diseases in humans. Therefore, studies designed to decipher the 
molecular and epigenetic regulators of SHF development are significant.  
As uncommitted mesodermal cells are specified towards the cardiac lineage, their 
genomes are epigenetically remodeled to “lock in” the cells to a cardiogenic fate (Wanstand et 
al., 2012; Bondue et al., 2011). However, the exact epigenetic mechanism underlying this fate 
commitment remains elusive. Pioneering work has established that well-conserved Polycomb 
group (PcG) proteins, which mediate transcriptional repression via epigenetic silencing of target 
genes, are essential for regulating various developmental programs, including heart 
development. PcG proteins are classified into two major functionally distinct complexes, the 
Polycomb Repressive Complex 1 (PRC1) and PRC2 (van der Stoop et al., 2008; He et al., 
2012; Delagado-Olguin et al., 2012; Illingworth et al., 2015; Voncken et al., 2003). The major 
components of PRC2 are Enhancer of Zeste 2 (EZH2), Embryonic Ectoderm Development 
(EED), and Suppressor of Zeste 12 (SUZ12). EZH2 is the catalytic subunit of PRC2, whereas, 
EED and SUZ12 are necessary for promoting EZH2 enzymatic activity, stabilizing the complex, 
and recognizing substrates (Morey and Christoffels, 2010; Wang et al., 2013; Müller et al., 
2009). These genes work canonically with and, in some instances, independent of PRC1 to 
regulate tissue-specific differentiation through repression of other transcriptional programs 
which is initiated via H3K27me3 by EZH2. The main components of PRC1 are ubiquitin E3 
ligase, Ring finger protein 1 (RING1A/B) -only Ring1b/Rfn2 homolog in zebrafish-, 
Chromodomain (CBX), Polyhomeotic homolog 1 (PHC/RAE28), and Polycomb group RINGB 
finger protein 4 (PCGF4/BMI1) (Morey and Helin, 2010; Wang et al., 2013; Müller et al., 2009). 
In this complex, Ring1B is the catalytic subunit that ubiquitinates H2AK119 upon CBX 
recognition of the H3K27me repressive epigenetic marker (van der Stoop et al., 2008; He et al., 
2012; Delagado-Olguin et al., 2012; Illingworth et al., 2015; Voncken et al., 2003; Morey and 
Helin 2010; Kerppola, 2009). 
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Until recently, investigations of the roles of PcG proteins in early vertebrate heart 
development have been hindered by the embryonic lethal phenotypes observed in mammalian 
knockout of several PcG proteins that arise during gastrulation, prior to FHF and SHF 
specification. Interestingly, all three polycomb genes of PRC2 are crucial for embryonic 
development, as Ezh2 (He et al., 2012), Eed (Faust et al., 1995), and Suz12 (Pasini et al., 2014; 
Pasini et al., 2007; He et al., 2012) mutant mice all display severe defects during gastrulation. 
Suz12−/− embryos die around E7 due to global loss of H3K27me3 and Ezh2 destabilization 
(Pasini et al., 2004; Pasini et al., 2007). Using a tissue-restrictive conditional inactivation 
approach, He et al. (2012) showed that Ezh2 is involved in regulating heart formation early 
cardiogenesis. Inactivation of Ezh2 in mice caused congenital heart defects that were 
embryonic lethal, including, hypertrabeculation, compact myocardial hypoplasia, and ventricular 
septal defects. Perinatal lethality and thinning of the myocardium were also observed in Eed-
deficient differentiated cardiomyocytes (He et al., 2012). Findings from these and other studies 
demonstrate the critical role of PRC2 proteins in regulating normal development, particularly 
expression of genes essential for early embryogenesis. 
Notably, mutations in polycomb proteins of PRC1 have varying effects on cardiogenesis, 
as some mouse mutants are able to survive beyond gastrulation and display mild or mostly 
postnatal abnormalities. Though mouse embryos devoid of Phc1 (also known as Rae28) display 
defective cardiac looping, the heart is still able to form chambers and mutants survive to 
adulthood (Shirai et al., 2002; Wang, 2012). Knockdown or overexpression of Cbx proteins in 
ESCs leads to impaired differentiation, de-repression of PRC1 target genes, and decreased 
proliferation (Morey and Christoffels, 2010; O’Loghlen et al., 2012; Ma et al., 2014). Though 
genetic deletion of Bmi1 resulted in postnatal lethality caused in anterior-posterior specification, 
there was no effect on cardiogenesis. Unlike its PRC1 counterparts, Ring1b null mice are 
embryonic lethal at gastrulation due to incomplete growth of embryonic and extraembryonic 
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tissues, reminiscent of the early lethal phenotype observed in mouse Ezh2 and Eed knockouts 
(Voncken et al., 2003).  
van der Velden et al. (2012) showed that, in contrast to Ring1b knockout mice, ring1b 
mutant zebrafish survive early embryonic development. The ring1b knockout zebrafish was 
generated using zinc finger nuclease (ZFN)-mediated targeted gene activation. Within the ZFN 
target site, one of the mutations led to deletion of 14 base pairs (Δ14 mutation). This 14 base 
pair deletion resulted in an open reading frame-shift that led to a premature stop codon (van der 
Velden et al., 2012). To confirm that the mutant allele was a functional null, ring1b mRNA and 
protein expression were assessed. ring1b mRNA was not detected in mutant embryos and 
Ring1b protein and mono-ubiquitination of H2A were also not detected in ring1b mutants at 72 
hours post fertilization (van der Velden et al., 2012). The study also demonstrated that Ring1b is 
essential for zebrafish pectoral fin development (van der Velden et al., 2012).  
Further, another study by van der Velden et al. (2013) showed that Ring1b is also 
responsible for regulating the developmental program of craniofacial cell lineages, as ring1b 
mutant embryos display severe craniofacial abnormalities (van der Velden et al., 2013). 
Numerous studies have reported that craniofacial muscles and heart cells from the SHF share a 
common origin (Nagelberg et al., 2015; Tzahor, 2009). Thus, the zebrafish mutant provides a 
good model for examining Ring1b’s role in cardiogenesis, such as FHF and SHF development 
(Harel et al., 2009; Tzahor, 2009; Nagelberg et al., 2015). In our study, we found that ring1b 
mutant hearts fail to loop and are significantly smaller than control hearts. Further, these 
phenotypes worsened over time, resulting in a stretched and stringy heart. Interestingly, these 
heart phenotypes are reminiscent of previously reported SHF-deficient phenotypes (Cai et al., 
2003; Zhou et al., 2011; Lazic et al., 2011; Vincent et al., 2010; Grifone et al., 2008; Lyons et al., 
1995; Kelly, 2012; van der Velden et al., 2013). Taken together, our findings suggest that 
Ring1b plays an essential role in SHF development.  
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Results  
Ring1b mutant displays cardiac defects that are initially distinct at 48 hpf. 
To visualize cardiogenesis in the absence of ring1b, we crossed the ring1bΔ14 allele 
with Tg(nkx2.5:ZsYellow) transgenic zebrafish, which fluorescently labels FHF- and SHF-
derived cells, and imaged resulting ring1b mutant and control hearts at 24, 48, and 72 hpf. 
These time points reflect the main stages of cardiogenesis. We observed defective ventricle 
formation, including an unlooped and stringy heart, in ring1b mutants compared to control 
ventricles (Fig. 12A-F), most noticeably at 48 hpf (Fig. 12E), the time point following SHF-
mediated contributions to the heart. Since ring1b mutants display ventricles that are smaller 
than control hearts, we wanted to determine if the phenotype observed was due to a reduction 
in ventricular CM numbers or in size of CMs. To quantify CM number, we used control and 
ring1b mutant Tg(cmlc2:nucDsRed) transgenic lines, which fluorescently labels the nuclei of 
mature cardiomyocytes with DsRed. We then collected confocal images of control and ring1b 
mutant double transgenic hearts at 48 hpf, following linear heart tube formation by FHF 
progenitors and when the heart chambers are formed. The number of nuclei in control and 
ring1b mutant hearts was quantified using ImageJ software. We observed that ring1b mutants 
had significantly fewer ventricular cardiomyocytes compared to the control embryos (Figs. 13A-
C), yet there was no significant difference in the number of atrial cardiomyocytes between 
mutant and control embryos (data not shown). Taken together, these findings suggest that the 
heart defect in ring1b mutants may arise during SHF-mediated development. 
 
Inhibition of Ring1b activity between 24-72 hpf recapitulates unlooped heart phenotype 
observed in mutant embryos 
 Of note, the heart phenotype observed in ring1b mutants is strikingly similar to that of 
zebrafish lines harboring mutations in other genes that regulate SHF dynamics, such as an 
unlooped and stringy-like heart with a significantly small ventricle (Nevis et al., 2013; Zhou et al., 
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2011). Given that the initial heart tube is formed in ring1b mutants and the robust heart defects 
displayed are associated with the two processes that SHF-derived cells are involved in (i.e. 
expansion of heart tube and looping), we hypothesized that the cardiac defects observed in 
ring1b mutants are caused by one or more aberrant SHF developmental processes: SHF 
progenitor specification, proliferation/ migration, and/or differentiation. Should this be the case, it 
would be helpful to know when during cardiogenesis CPC behavior is perturbed. To this end, we 
used Tg(nkx2.5:ZsYellow) wildtype embryos, in which all CPCs were labeled with ZsYellow, and 
treated with 5 µM PRT4165. PRT4165 is a potent inhibitor of both RING1B/RNF2 and RING1A, 
which are responsible for the E3 ubiquitin ligase activity found in PRC1 (Ismail et al., 2013). The 
drug also inhibits the ubiquitin signaling at DNA double stranded breaks (Ismail et al., 2013) and 
may also inhibit BMI-1, another component of the PRC1 complex. After treatment with PRT4165 
at different time intervals from gastrulation to formation of the heart (5-72 hpf), we observed that 
Ring1b inhibition from 24-72 hpf (Fig. 14A) results in a small, unlooped heart, which 
recapitulates the phenotypes observed in ring1b mutants (Fig. 14C), while DMSO-treated 
mutants displayed a normal heart phenotype (Fig. 14B). This data is promising as it provides 
preliminary, yet valuable insight into the temporal requirement of Ring1b during early 
cardiogenesis.  
 
ring1b mutants display little to no presence of late differentiated SHF-derived cells at 
arterial pole region of the heart 
 Based on our preliminary data, ring1b mutants display cardiac defects, such as a small 
ventricle due to fewer ventricular CMs, along with an unlooped and stretched heart. These 
defects may be due to perturbations in FHF or SHF-derived CMs. Further study indicated that 
the expression of Elastin 2, a marker of SHF-derived OFT smooth muscle cells, was drastically 
reduced in the arterial pole region of ring1b mutant hearts (Figs. 15B-B”) compared to control 
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hearts (Figs. 15A-A”). We thus hypothesize that SHF-development is primarily impacted with 
ring1b-deficiency in zebrafish embryos.  
The tightly controlled SHF developmental process not only requires proper specification 
of the lateral plate mesodermal cells of SHF progenitors but also highly regulated differentiation 
of these progenitors into mature cardiomyocytes (Brown et al., 2016; Kelly, 2012; Camarata et 
al., 2010). To determine whether cellular differentiation, a critical event in SHF development, is 
altered, we investigated the possibility that the looping defect in the ring1b mutant might be due 
to improper SHF progenitor differentiation. To observe SHF cardiomyocyte differentiation, we 
utilized a cardiomyocyte photoconversion assay to quantify FHF- and SHF-derived ventricular 
cardiomyocytes at 48 hpf. The assay employs the transgenic strain Tg(nkx2.5:Kaede), which 
continuously expresses the photoconvertible green-red proteins in nkx2.5-expressing 
cardiomyocyte nuclei. We photoconverted nkx2.5+ heart tubes of control and ring1b mutant 
embryos at 24 hpf and performed confocal imaging on the same hearts in both the green and 
red channels at 48 hpf. The double-labeled cells are the early differentiating cardiomyocytes 
from the FHF and the single labeled, green+ cells are those that differentiated following 
photoconversion from the SHF (Fig. 15C). If there is a differentiation defect, then significantly 
lower percentages or expression level of single-labeled (green only) late differentiating 
cardiomyocytes will be detected in ring1b mutant hearts. In our study, initial observations reveal 
the appearance of little to no expression of single-labeled (green only) late differentiating 
cardiomyocytes at the arterial pole in ring1b mutant hearts, owing to the inability of SHF 
progenitors to differentiate (Figs. 15D-E). Notably, this result does not explicitly conclude that 
specification is unaffected in ring1b mutant, in which fewer or no progenitors are generated. 
Indeed, these experiments should be repeated and the number of double positive and single 
positive (green only) cardiomyocyte nuclei in Tg(myl7:nlskikGR) control and ring1b mutant 
hearts should be quantified. Nevertheless, this data provides insight into the possible role of 
Ring1b in SHF cellular differentiation.  
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Materials and Methods 
Zebrafish husbandry and strains 
All animals were maintained at the aquaculture facility of the University of North Carolina 
at Chapel Hill in accordance with Institutional Animal Care and Use Committee approved 
protocols. We used the following transgenic and mutant lines: ring1b mutants (van der Velden et 
al., 2012), Tg(-36nkx2.5:ZsYellow)fb7 (Zhou et al., 2011); Tg(myl7:dsRed2-nuc)f2 (Mably et al., 
2003); and TgBAC(-36nkx2.5:Kaede)fb9 (Zhou et al., 2011). ring1b mutant embryos were 
identified by performing PCR followed by digestion with restriction enzyme Taq1 to identify 
the ring1bΔ14allele (van der Velden et al., 2012). 
 
Immunostaining  
Immunohistochemistry was performed as previously described (Zhou et al., 2011) using 
primary antibody Elastin-2 (1:1000; Burns Lab) and secondary antibodies Alexa Fluor 555 goat 
anti-rabbit IgG2b, Alexa Fluor 488 goat anti-mouse IgG2b or Alexa Fluor 546 goat anti-mouse 
IgG2b (all 1:200). 
 
Confocal imaging and analysis 
Zebrafish embryos were anesthetized using 1X Tricaine (Sigma) and mounted with 1% 
low-melting agarose (Sigma) in embryo medium or system water for optimal visualization of 
heart. Heartbeat was ceased before imaging using 5-10X Tricaine (Sigma). Images were 
obtained with an Olympus Fluoview 1000MPE, multiphoton, upright confocal microscope 
equipped with a 20X XLPlan (NA 1.0) water immersion objective with 1.0X or 3.0X digital zoom 
and 1024x1024 pixels resolution. Confocal z-stacks were collected using the Fluoview software 
with a 2.50 µm step size acquisition through the heart tissue. 488 nm and 599 nm lasers were 
used to excite GFP and RFP. Each channel was acquired sequentially to avoid bleed through 
and signal attenuation due to increasing depth was taken into account by using the software's 
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brightness correction algorithm. Confocal images were collected for a minimum of 5 embryos for 




Live TgBAC(-36nkx2.5:Kaede)fb9 embryos were placed in plastic Petri dishes with 
0.4%Tricaine, to limit excessive mobility. After removing foil and prior to photoconversion, 
embryos were pre-screened for immediate photoconversion. After confirming that no conversion 
occurred, embryos were photoconverted with EVOS FL Auto software (Life Technologies) by 
manually exposing embryos to DAPI laser for 3-5 minutes. Embryos were then covered in foil 
and placed in 28.5°C incubator. Post-photoconversion images were collected with the 488 nm 
and 546 nm lasers at 48 hpf. Embryos were carefully embedded in 1% agarose and then 
extracted to be raised individually for additional analysis.  
 
Drug treatment  
Pharmacological inhibitors were stored in DMSO (Fisher Scientific) stocks. Embryos 
were treated with drugs, 5 µM 2-pyridine-3-yl-methylene-indan-1,3-dione (PRT4165) (Santa 
Cruz Biotech), diluted in egg water (1.5 mL stock salts added to 1 L distilled water) and 
supplemented with 0.003% 1-phenyl 2-thiourea (PTU) (Sigma) and DMSO to 1% final. Control 
embryos were incubated with 1% DMSO vehicle. Embryos were dechorionated and treated with 
DMSO or PRT4165 at multiple time points. 
 
Statistical analysis 
The data shown in the graph are represented as mean ± SEM. Statistical significance 
was determined between groups with a two-tailed Student’s t-test. 
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Figure 12 ring1b mutant displays cardiac defects that are initially distinct at 48 hpf  
(A, D) Lateral view of linear heart tube at 24 hpf in control and ring1b mutant. (B, E) Ventral view of 2-
chambered hearts at 48 hpf. Note: mutant heart is unlooped. (C, F) Ventral view of control and ring1b 





Figure 13 Small ventricle size observed in ring1b mutants is due to fewer ventricular CMs 
(A-B’) Maximal projection (ventral view) of CM nuclei in control and ring1b mutant hearts at 48 hpf. (C) 
Quantification of DsRed+ ventricular CMs (n = 5-8) at 48 hpf in control and ring1b mutant hearts. V, 







Figure 14 Inhibition of Ring1b activity between 24-72 hpf recapitulates “unlooped” heart 
phenotype observed in mutant embryos  
(A) Schematic of experimental design. (B-C) Maximal projection (ventral view) of DMSO- and PRT4165-





Figure 15 ring1b mutants display little to no presence of late differentiated SHF-derived 
cells at arterial pole region of heart 
(A-B’’) Maximal projections of hearts at 72 hpf from control and ring1b mutant hearts stained with 
ZsYellow (A, B), Eln2 (A’, B’), or merged (A”, B”). (C) Schematic of experimental design for 
photoconversion assay in D-E. (D-E) Maximal projections (ventral view) of hearts at 48 hpf from control 
and ring1b mutants.  
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3.3 Significance and Future Directions 
Significance  
Though this work has not yet been completed, the data presented in Chapter 3 
regarding Ring1b’s involvement in cardiogenesis is quite novel to our knowledge. The precise 
regulation of CPC dynamics during cardiac development is essential, as defects in early 
embryonic development can cause congenital heart disease (McCulley and Black, 2012; Brand 
et al., 2003; Bruneau et al., 2008; Kelly, 2012). Little is known about how Ring1b/Rfn2 affects 
SHF development, which might be perturbed in many CHD patients. Additionally, factors and 
mechanisms that mediate growth in development can be harnessed to repair adult hearts 
following various cardiomyopathies, particularly myocardial infarction (Amini et al., 2017; 
Cyganek et al., 2013). 
Though Ezh2, the core component of PRC2, has been described to be important for CM 
proliferation, survival, and homeostasis, and other factors, Eed and Jarid2, have been 
implicated in heart formation (Collinson et al., 2016; He et al., 2012; Pasini and Di Croce, 2016; 
Pietersen et al., 2008; Surface et al., 2010), to date, there have not been substantial studies of 
the core component of PRC1, Ring1b’s role, in early cardiac development. This is likely 
because Ring1b mutant mice die during gastrulation due to failure of normal epiblast expansion 
and improper migration of the mesoderm (Vonchen et al., 2003). Many studies have reported 
common lineage relationships between head muscles and second heart field derivatives in 
mouse embryos and in zebrafish (Harel et al., 2009; Tzahor, 2009; Nagelberg et al., 2015). 
Given that ring1b zebrafish mutants have defects in their pectoral fin, craniofacial muscles, and 
heart (i.e. looping), as explored in our work, this suggests that Ring1b could be crucial in SHF 
development. Preliminary phenotypic analysis of ring1b zebrafish mutant hearts suggests that 
Ring1b is involved during SHF progenitor contribution to the arterial pole of the heart and 
possibly CPC differentiation. In wildtype embryos, suppression of ring1b using a small molecule 
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inhibitor recapitulated the unlooped heart phenotype observed in the zebrafish mutant between 
24-72 hpf, thus providing insight into the potential temporal requirement of Ring1b.  
 
Future Directions and Additional Interpretations 
As discussed in Chapter 3.2, additional studies are necessary for precise 
characterization of ring1b mutant zebrafish. Therefore, below are experimental approaches that 
can be performed to further test the hypothesis that Ring1b is essential for SHF development.  
 
Generate zebrafish cardiac-specific ring1b conditional knockout 
Since Ring1b is likely ubiquitously expressed throughout various tissues and cell types 
in the embryo, it will be vital to clearly distinguish and establish its role in the developing heart. 
To determine whether Ring1b is specifically involved in cardiogenesis, a gateway cloning 
system approach using elements in the CRISPR/Cas9 vector (described in Ablain et al., 2015; 
Zhou et al., 2018) can be used to generate a cardiac-specific conditional knockout of ring1b in 
the zebrafish embryo. Results from this key experiment will reveal or rather further demonstrate 
Ring1b’s requirement in early cardiovascular development, without having off target effects in 
other tissues. 
 
Determine the requirement and timing of Ring1b in SHF progenitor processes: 
specification, migration/proliferation, and differentiation 
Recent studies in E9.5 mouse embryos reveal that polycomb proteins of PRC1, Ring1b, 
Bmi1/Pcgf4, and Rae28/Phc1 are expressed throughout the embryonic heart in regions 
containing the FHF and SHF (Shirai et al., 202; Koga et al., 2002). Similar to mice, zebrafish 
Ring1b might also be ubiquitously distributed in the embryo. Even if Ring1b is found to be 
ubiquitously expressed in the zebrafish embryo, it is still plausible that ring1b zebrafish mutants 
display more distinct and restricted CPC phenotypes. First, to examine the spatio-temporal 
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expression of ring1b at different stages of heart development, whole mount in situ hybridization 
can be performed at multiple time points in control embryos. This method can also be used to 
confirm that ring1b transcripts are localized specifically to cardiac progenitor cells by examining 
co-localization of ring1b transcripts with the cardiac progenitor marker nkx2.5 at 20.5 hpf, during 
the somite stage, and at 24 hpf, during the linear heart tube stage. Additionally, co-localization 
of ring1b transcripts can be evaluated with probes for ltbp3 and isl2a/b, SHF-specific markers, 
and cmlc2 (also known as myl7), the myocardial marker, at 24, 36, and 48 hpf.  
Analyzing expression of known SHF marker genes in ring1b mutants is also important to 
determine whether the location and relative expression of each transcript is perturbed, thus 
suggesting that observed defects may be due to dysregulation of SHF specification and/or 
differentiation in mutant hearts. The reduced number of cardiomyocytes observed in ring1b 
mutant ventricles is likely caused by defective SHF dynamics. However, as previously 
discussed, the zebrafish ventricle is composed of CMs differentiated from both FHF and SHF 
progenitors, with each group contributing to ~ 50% of the ventricle. Therefore, it is plausible that 
a reduction in ventricular CM number can manifest from defects in the FHF progenitor pool. 
Since ring1b mutants successfully form the primitive linear heart tube, it is likely that the FHF 
cells are not impacted by ring1b deficiency. Nevertheless, the total number of FHF-derived CMs 
that contribute to the heart tube, at ~26 hpf, should be quantified to confirm that hypothesis. 
An important process of proper looping morphogenesis and expansion of the heart is the 
accretion of SHF cells at the poles of the heart tube (Kelly, 2012; Camarata et al., 2010). 
Though the looping defect in the ring1b mutant may be due to dysregulated specification of SHF 
progenitors, it is possible that the ring1b deficiency in the embryos are affecting proliferation of 
SHF progenitors at the poles of the linear heart tube. To further investigate this hypothesis, the 
proliferation index within SHF-derived cells can be measured using control and ring1b mutant 
Tg(nkx2.5:nucZsYellow; cmlc2:nucDsRed) double transgenic lines. Control and mutant embryos 
can be pulse-labeled with EdU at 20 hpf, prior to heart tube formation, and then fixed embryos 
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can be collected for immunohistochemistry at 24 and 36 hpf to quantify the percentage of 
ZsYellow+, DsRed-, EdU-stained cells in both genotypes. If there is a proliferation defect, fewer 
nkx2.5-expressing cells will be observed in ring1b mutant hearts. Alternatively, assays for other 
cell cycle markers of DNA replication and mitosis, such as PCNA or phospho-histone 3, 
respectively, can be employed.  
In addition to repeating the temporal, inhibition experiments with PRT4165 in wildtype 
embryos, it will be important to further investigate whether the drug simply arrests development 
of the whole embryo, or if there is any cardio-specificity to the observed phenotypes. 
Additionally, for PRT4165 inhibition experiments, confirmation of undetectable mono-
ubiquitinated histone H2A in ring1b-treated embryos will be necessary to ensure Ring1b’s 
catalytic activity is repressed. 
 
Identify the molecular mechanism by which Ring1b regulates SHF dynamics 
Though, our data shows that Ring1b is involved in cardiogenesis, it does not necessarily 
attribute this to Ring1b’s function as an epigenetic regulator. To this end, mRNA injections can 
be used in ring1b mutants to rescue the epigenetic regulation function and investigate whether 
the cardiac defects observed in the mutant embryos are also attenuated. Western blot analysis 
should follow to confirm that mono-ubiquitinated histone H2A is detected in mRNA injected 
ring1b mutant embryos.  
Transcriptional dysregulation in CPC dynamics is associated with many congenital heart 
diseases (Olson and Srivastava, 1996; Rochais et al., 2009; Waardenberg et al., 2014; 
Wanstad et al., 2012). Ring1B acts as a repressor of downstream genes involved in 
development; however, the direct targets of Ring1B during SHF specification remains unknown. 
Therefore, high-throughput techniques must be employed to determine, at the cellular and 
molecular level, the dysregulation of CPCs in ring1b mutant embryos.  
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The primary function of Ring1b is the ubiquitination of H2AK119. Therefore, to identify 
direct targets of Ring1b in the context of zebrafish cardiogenesis, chromatin 
immunoprecipitation (ChIP) can be employed using zebrafish embryos at different stages of 
early development and antibodies against the H2AK119ub1 histone modification mark, coupled 
with sequencing (ChIP-seq).  This direct experiment can reveal what specific gene locus is 
affected by Ring1b. Additional histone markers can also be evaluated: repressive (ex. 
H3K27me) and active (ex. H2K4me2/me3) histone markers. 
SHF progenitors contribute to the head and heart muscles and to the endothelium of the 
pharyngeal arch arteries. Specifically, nkx2.5-expressing mesoderm gives rise to heart muscle 
as well as posterior pharyngeal arch arteries (pAAs) endothelium in mice and fish (Nagelberg et 
al., 2015). These data suggest that head muscles, the heart muscle, and pharyngeal arch 
arteries share a common origin. Nagelberg et al. (2015) showed that in zebrafish the pAAs 
progenitor cells arise from a small population of head mesodermal cells that co-express the 
cardiac marker nkx2.5 and tcf21, a head myoblast marker. Nagelberg et al. (2015) also found 
that the posterior pAA progenitors require the transcription factors nkx2.5 and tcf21 for their 
specification.  
These findings are relevant to our study because conducting FACS with ring1b mutant 
embryos can be challenging since embryos have to be sacrificed to perform PCR and digestion 
reactions for identification of the mutant and control embryos. To circumvent this problem, 
Tg(tcf21:nucGFP) control and ring1b mutants can be utilized. Tcf21, the head myoblast marker, 
is expressed at very early time points (i.e. 15 hpf). Since it has been previously reported that 
ring1b mutants have a defective head muscle lineage (van der Velden et al., 2013), reduced or 
absent expression of tcf21 in embryos can be used for early identification of ring1b mutants. 
Indeed, for initial experiments, selected Tg(tcf21:nucGFP) ring1b embryos should be genotyped 
to ensure that reduced or no tcf21 expression is sufficient for distinguishing the genotypes. 
Though not as direct as the previously proposed experiments, temporal isolation of tcf21-GFP+ 
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cells from control and mutant embryos at earlier stages of cardiogenesis can be sorted via 
FACS combined with RNAseq or gene expression microarrays for transcription enrichment 
profiling and GO pathway analysis. 
 
Identify the canonical components of PRC1 involved in zebrafish cardiogenesis 
Numerous studies have identified PcG proteins that belong to canonical PRC1. 
However, it has also been reported that there are several non-canonical PRC1 complexes, and 
that the importance and dosage of various PRC1 proteins within a complex varies in different 
cell types (Kerppola et al., 2009). This is because individual PcG proteins recruit distinct 
associated proteins and gene targets. Thus, combinations of PRC1 complexes can prompt 
profoundly different functions within a cell or tissue (Kerppola et al., 2009; Bajusz et al., 2018). 
In fact, during certain developmental events cells can “decide” to exchange one PcG protein for 
another type of PcG protein (Bajusz et al., 2018). Therefore, a deeper understanding of which 
specific PRC1 components are interacting with Ring1b in zebrafish cardiac development will 
provide insights into the role of PRC1 in lineage commitment and differentiation processes 
during cardiovascular development in zebrafish. To this end, ChIP-seq can also be coupled with 
mass spectrometry to identify the protein-binding partners in the PRC1 complex in zebrafish 
embryos.
83 
CHAPTER 4 CONCLUSIONS 
The studies described herein provide valuable insights into the molecular mechanisms 
necessary for proper zebrafish heart development at early and late stages. Specifically, 
experiments in Chapter 2 clearly reveal the cellular and functional consequences that arise due 
to loss of trabeculae. We found that trabeculae-deficient erbb2 mutant hearts display a 
hypertrophic phenotype that seems to be initially compensatory for the increase in 
hemodynamic burden and cardiac output workload. However, pathological hypertrophy ensues 
in the absence of heart’s normal internal infrastructure. Pharmacological inhibition of mTOR did 
attenuate the HL phenotypes observed in the mutant heart. This body of evidence also 
highlights one of many advantages for using zebrafish as a model organism for studying CHDs 
and assessing the effectiveness of small molecules for therapy. Overall, the data shown in 
Chapter 2 is one of the first queries that denotes the function of trabeculae during cardiac 
maturation and in promoting efficient cardiovascular homeostasis in the growing organism.  
In Chapter 3, we sought to characterize the role of PRC1 core component, Ring1b, in 
SHF-mediated development by investigating the molecular process that is perturbed in ring1b 
zebrafish mutants that display a diminutive heart phenotype. To our knowledge, though the role 
of PRC1 and PRC2 complexes in lineage specification, hematopoiesis, and differentiation have 
been well-studied by utilizing complete or conditional knockouts of PcG proteins in vitro and in 
vivo, the preliminary data in Chapter 3 are the first in vivo studies of Ring1b’s role, specifically in 
early cardiac progenitors. Nevertheless, a comprehensive analysis to decipher the spatio-
temporal requirement of Ring1b during key aspects of SHF-mediated development is still 
needed. Furthermore, identifying the direct targets of Ring1b and the components of PRC1 in 
zebrafish cardiogenesis via ChIP-seq and mass spectrometry will provide invaluable information 
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into the importance of Ring1b epigenetic regulation during cardiovascular development and 
disease.  
 Ultimately, understanding the genetic and epigenetic causes of congenital heart 
diseases can inform optimal preventative measures, genetic counseling, pre-natal diagnoses, 
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